CN116367838A - 结晶5-(二甲基氨基)-n-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐二水合物 - Google Patents
结晶5-(二甲基氨基)-n-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐二水合物 Download PDFInfo
- Publication number
- CN116367838A CN116367838A CN202180069848.8A CN202180069848A CN116367838A CN 116367838 A CN116367838 A CN 116367838A CN 202180069848 A CN202180069848 A CN 202180069848A CN 116367838 A CN116367838 A CN 116367838A
- Authority
- CN
- China
- Prior art keywords
- compound
- disease
- patient
- mapk
- determined
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 title claims abstract description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 109
- 238000000034 method Methods 0.000 claims abstract description 97
- 238000011282 treatment Methods 0.000 claims abstract description 43
- 150000001875 compounds Chemical class 0.000 claims description 309
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 150
- 201000010099 disease Diseases 0.000 claims description 121
- 102000043136 MAP kinase family Human genes 0.000 claims description 74
- 108091054455 MAP kinase family Proteins 0.000 claims description 74
- 238000002844 melting Methods 0.000 claims description 55
- 230000008018 melting Effects 0.000 claims description 55
- 206010028980 Neoplasm Diseases 0.000 claims description 39
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 34
- 230000002401 inhibitory effect Effects 0.000 claims description 31
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 30
- 208000035475 disorder Diseases 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 28
- 230000004580 weight loss Effects 0.000 claims description 24
- 238000002411 thermogravimetry Methods 0.000 claims description 19
- 208000023275 Autoimmune disease Diseases 0.000 claims description 17
- 208000027866 inflammatory disease Diseases 0.000 claims description 16
- 230000005855 radiation Effects 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 12
- 230000000977 initiatory effect Effects 0.000 claims description 12
- 239000000155 melt Substances 0.000 claims description 12
- 208000011580 syndromic disease Diseases 0.000 claims description 12
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 10
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 10
- 230000001419 dependent effect Effects 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 102000004127 Cytokines Human genes 0.000 claims description 9
- 108090000695 Cytokines Proteins 0.000 claims description 9
- 230000004044 response Effects 0.000 claims description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 9
- 206010069351 acute lung injury Diseases 0.000 claims description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 206010025135 lupus erythematosus Diseases 0.000 claims description 7
- 229910017488 Cu K Inorganic materials 0.000 claims description 6
- 229910017541 Cu-K Inorganic materials 0.000 claims description 6
- 206010011878 Deafness Diseases 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 230000002074 deregulated effect Effects 0.000 claims description 6
- 230000010370 hearing loss Effects 0.000 claims description 6
- 231100000888 hearing loss Toxicity 0.000 claims description 6
- 208000016354 hearing loss disease Diseases 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 230000008497 endothelial barrier function Effects 0.000 claims description 5
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 230000004890 epithelial barrier function Effects 0.000 claims description 4
- 210000000265 leukocyte Anatomy 0.000 claims description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 3
- 206010028289 Muscle atrophy Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
- 230000032677 cell aging Effects 0.000 claims description 3
- 201000010893 malignant breast melanoma Diseases 0.000 claims description 3
- 239000003226 mitogen Substances 0.000 claims description 3
- 230000032258 transport Effects 0.000 claims description 3
- 101000945093 Homo sapiens Ribosomal protein S6 kinase alpha-4 Proteins 0.000 claims description 2
- 208000004852 Lung Injury Diseases 0.000 claims description 2
- 101000822651 Oryza sativa subsp. japonica Serine/threonine-protein kinase SAPK1 Proteins 0.000 claims description 2
- 102100033644 Ribosomal protein S6 kinase alpha-4 Human genes 0.000 claims description 2
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 2
- 231100000515 lung injury Toxicity 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 abstract description 17
- 239000003112 inhibitor Substances 0.000 description 78
- -1 for example Substances 0.000 description 52
- 239000000203 mixture Substances 0.000 description 24
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 24
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000003814 drug Substances 0.000 description 20
- 208000024891 symptom Diseases 0.000 description 18
- 102000005962 receptors Human genes 0.000 description 17
- 108020003175 receptors Proteins 0.000 description 17
- 238000009472 formulation Methods 0.000 description 16
- 230000027455 binding Effects 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 12
- 229940124597 therapeutic agent Drugs 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 201000009030 Carcinoma Diseases 0.000 description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 10
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- 229940126560 MAPK inhibitor Drugs 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 238000013268 sustained release Methods 0.000 description 9
- 239000012730 sustained-release form Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 206010039491 Sarcoma Diseases 0.000 description 8
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000003111 delayed effect Effects 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 206010009944 Colon cancer Diseases 0.000 description 7
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 239000008016 pharmaceutical coating Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 208000003174 Brain Neoplasms Diseases 0.000 description 6
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 6
- 206010018338 Glioma Diseases 0.000 description 6
- 108010024636 Glutathione Proteins 0.000 description 6
- 208000034578 Multiple myelomas Diseases 0.000 description 6
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 6
- 208000006265 Renal cell carcinoma Diseases 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- 206010017758 gastric cancer Diseases 0.000 description 6
- 208000005017 glioblastoma Diseases 0.000 description 6
- 229960003180 glutathione Drugs 0.000 description 6
- 208000014829 head and neck neoplasm Diseases 0.000 description 6
- 229960004618 prednisone Drugs 0.000 description 6
- 201000011549 stomach cancer Diseases 0.000 description 6
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 5
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 5
- 206010005003 Bladder cancer Diseases 0.000 description 5
- 108010092160 Dactinomycin Proteins 0.000 description 5
- 208000003445 Mouth Neoplasms Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- 229930012538 Paclitaxel Natural products 0.000 description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 108010008038 Synthetic Vaccines Proteins 0.000 description 5
- 229960000548 alemtuzumab Drugs 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 229960004679 doxorubicin Drugs 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 229960004942 lenalidomide Drugs 0.000 description 5
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 5
- 230000006780 non-homologous end joining Effects 0.000 description 5
- 229960001592 paclitaxel Drugs 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 5
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 5
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- 206010003571 Astrocytoma Diseases 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 4
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 4
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 4
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 4
- 208000032612 Glial tumor Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 4
- 101710120843 Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 4
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 4
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 4
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 4
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 4
- 206010029260 Neuroblastoma Diseases 0.000 description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 4
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 description 4
- 206010057644 Testis cancer Diseases 0.000 description 4
- 208000008383 Wilms tumor Diseases 0.000 description 4
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 description 4
- 102100035535 Zinc finger protein GLI1 Human genes 0.000 description 4
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 229960000397 bevacizumab Drugs 0.000 description 4
- 229960001602 ceritinib Drugs 0.000 description 4
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 229960000640 dactinomycin Drugs 0.000 description 4
- 229960002448 dasatinib Drugs 0.000 description 4
- 238000013265 extended release Methods 0.000 description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 4
- 201000009277 hairy cell leukemia Diseases 0.000 description 4
- 201000010536 head and neck cancer Diseases 0.000 description 4
- 230000013632 homeostatic process Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229960001507 ibrutinib Drugs 0.000 description 4
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 4
- 238000000099 in vitro assay Methods 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 201000005962 mycosis fungoides Diseases 0.000 description 4
- 229960001346 nilotinib Drugs 0.000 description 4
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 4
- 229960003359 palonosetron hydrochloride Drugs 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 229960004641 rituximab Drugs 0.000 description 4
- 201000000849 skin cancer Diseases 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229940083542 sodium Drugs 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 229960004964 temozolomide Drugs 0.000 description 4
- 201000003120 testicular cancer Diseases 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 3
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 3
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 3
- 108010024976 Asparaginase Proteins 0.000 description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 description 3
- 102000001805 Bromodomains Human genes 0.000 description 3
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 201000009047 Chordoma Diseases 0.000 description 3
- 208000006332 Choriocarcinoma Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 102000009465 Growth Factor Receptors Human genes 0.000 description 3
- 108010009202 Growth Factor Receptors Proteins 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 102100040018 Interferon alpha-2 Human genes 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- 108010079944 Interferon-alpha2b Proteins 0.000 description 3
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 3
- 208000018142 Leiomyosarcoma Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 208000000172 Medulloblastoma Diseases 0.000 description 3
- 206010027406 Mesothelioma Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 229960005524 O6-benzylguanine Drugs 0.000 description 3
- KRWMERLEINMZFT-UHFFFAOYSA-N O6-benzylguanine Chemical compound C=12NC=NC2=NC(N)=NC=1OCC1=CC=CC=C1 KRWMERLEINMZFT-UHFFFAOYSA-N 0.000 description 3
- 206010034277 Pemphigoid Diseases 0.000 description 3
- 229940049937 Pgp inhibitor Drugs 0.000 description 3
- 208000007641 Pinealoma Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 108091008611 Protein Kinase B Proteins 0.000 description 3
- 108700020978 Proto-Oncogene Proteins 0.000 description 3
- 102000052575 Proto-Oncogene Human genes 0.000 description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 description 3
- 201000000582 Retinoblastoma Diseases 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 108010016672 Syk Kinase Proteins 0.000 description 3
- 102000000551 Syk Kinase Human genes 0.000 description 3
- 108700012920 TNF Proteins 0.000 description 3
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 3
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 108091008605 VEGF receptors Proteins 0.000 description 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
- 229960004308 acetylcysteine Drugs 0.000 description 3
- 208000017733 acquired polycythemia vera Diseases 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 229960001097 amifostine Drugs 0.000 description 3
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000004410 anthocyanin Substances 0.000 description 3
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 3
- 229960002594 arsenic trioxide Drugs 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 229960002756 azacitidine Drugs 0.000 description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 201000001531 bladder carcinoma Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229960001467 bortezomib Drugs 0.000 description 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 3
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 3
- 229960004562 carboplatin Drugs 0.000 description 3
- 229960002438 carfilzomib Drugs 0.000 description 3
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 3
- 108010021331 carfilzomib Proteins 0.000 description 3
- 229960005243 carmustine Drugs 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 229960005395 cetuximab Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960000928 clofarabine Drugs 0.000 description 3
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 201000005619 esophageal carcinoma Diseases 0.000 description 3
- 229960005420 etoposide Drugs 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 229960005167 everolimus Drugs 0.000 description 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 229960002074 flutamide Drugs 0.000 description 3
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 3
- 229960002584 gefitinib Drugs 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 201000005264 laryngeal carcinoma Diseases 0.000 description 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 3
- 229960004338 leuprorelin Drugs 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 3
- 229960004296 megestrol acetate Drugs 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 229960001428 mercaptopurine Drugs 0.000 description 3
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 3
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 238000003032 molecular docking Methods 0.000 description 3
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 229960001756 oxaliplatin Drugs 0.000 description 3
- 229960004390 palbociclib Drugs 0.000 description 3
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 3
- OLDRWYVIKMSFFB-SSPJITILSA-N palonosetron hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 OLDRWYVIKMSFFB-SSPJITILSA-N 0.000 description 3
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 238000002428 photodynamic therapy Methods 0.000 description 3
- 229960003171 plicamycin Drugs 0.000 description 3
- 208000037244 polycythemia vera Diseases 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 230000000541 pulsatile effect Effects 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 206010038038 rectal cancer Diseases 0.000 description 3
- 201000001275 rectum cancer Diseases 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 3
- 229960001196 thiotepa Drugs 0.000 description 3
- 229960003087 tioguanine Drugs 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 3
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 3
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 2
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- FKSFKBQGSFSOSM-QFIPXVFZSA-N 1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-[6-(1-piperazinyl)-3-pyridinyl]-4-indolecarboxamide Chemical compound C1=C2N([C@@H](C)CC)C=C(C)C2=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C=C1C(C=N1)=CC=C1N1CCNCC1 FKSFKBQGSFSOSM-QFIPXVFZSA-N 0.000 description 2
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
- WNYFVEFUHMDIRQ-UHFFFAOYSA-N 4-(morpholin-4-ylmethyl)aniline Chemical compound C1=CC(N)=CC=C1CN1CCOCC1 WNYFVEFUHMDIRQ-UHFFFAOYSA-N 0.000 description 2
- KNTGXGBOYZAKTA-UHFFFAOYSA-N 4-[(4-nitrophenyl)methyl]morpholine Chemical compound C1=CC([N+](=O)[O-])=CC=C1CN1CCOCC1 KNTGXGBOYZAKTA-UHFFFAOYSA-N 0.000 description 2
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 2
- MKBLHFILKIKSQM-UHFFFAOYSA-N 9-methyl-3-[(2-methyl-1h-imidazol-3-ium-3-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;chloride Chemical compound Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 MKBLHFILKIKSQM-UHFFFAOYSA-N 0.000 description 2
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 102400000068 Angiostatin Human genes 0.000 description 2
- 108010079709 Angiostatins Proteins 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 239000005465 B01AC22 - Prasugrel Substances 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 229940124291 BTK inhibitor Drugs 0.000 description 2
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 102100029894 Bromodomain testis-specific protein Human genes 0.000 description 2
- 108050009021 Bromodomains Proteins 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 2
- VSEIDZLLWQQJGK-CHOZPQDDSA-N CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O Chemical compound CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O VSEIDZLLWQQJGK-CHOZPQDDSA-N 0.000 description 2
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 2
- 108010031425 Casein Kinases Proteins 0.000 description 2
- 102000005403 Casein Kinases Human genes 0.000 description 2
- 102100036158 Ceramide kinase Human genes 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 108010060248 DNA Ligase ATP Proteins 0.000 description 2
- 102100033195 DNA ligase 4 Human genes 0.000 description 2
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 2
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 2
- 102100023272 Dual specificity mitogen-activated protein kinase kinase 5 Human genes 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 239000012824 ERK inhibitor Substances 0.000 description 2
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010014967 Ependymoma Diseases 0.000 description 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 2
- 208000036566 Erythroleukaemia Diseases 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 241000027355 Ferocactus setispinus Species 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
- 208000007465 Giant cell arteritis Diseases 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- 108010069236 Goserelin Proteins 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 2
- 101001115390 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 5 Proteins 0.000 description 2
- 101000950687 Homo sapiens Mitogen-activated protein kinase 7 Proteins 0.000 description 2
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 2
- 229940043367 IDO1 inhibitor Drugs 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108010024121 Janus Kinases Proteins 0.000 description 2
- 102000015617 Janus Kinases Human genes 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 2
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 230000037364 MAPK/ERK pathway Effects 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000007054 Medullary Carcinoma Diseases 0.000 description 2
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 description 2
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 description 2
- 108010016076 Octreotide Proteins 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- 241000721454 Pemphigus Species 0.000 description 2
- 108030003690 Phosphatidylinositol-4,5-bisphosphate 3-kinases Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 229940078123 Ras inhibitor Drugs 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 201000010208 Seminoma Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 2
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 208000014070 Vestibular schwannoma Diseases 0.000 description 2
- 108010088665 Zinc Finger Protein Gli2 Proteins 0.000 description 2
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 2
- OUUYBRCCFUEMLH-YDALLXLXSA-N [(1s)-2-[4-[bis(2-chloroethyl)amino]phenyl]-1-carboxyethyl]azanium;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 OUUYBRCCFUEMLH-YDALLXLXSA-N 0.000 description 2
- 229960004103 abiraterone acetate Drugs 0.000 description 2
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 description 2
- RUGAHXUZHWYHNG-NLGNTGLNSA-N acetic acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5, Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 RUGAHXUZHWYHNG-NLGNTGLNSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000004064 acoustic neuroma Diseases 0.000 description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 description 2
- 208000037832 acute lymphoblastic B-cell leukemia Diseases 0.000 description 2
- 208000037833 acute lymphoblastic T-cell leukemia Diseases 0.000 description 2
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 2
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 2
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 2
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 2
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 229960001686 afatinib Drugs 0.000 description 2
- USNRYVNRPYXCSP-JUGPPOIOSA-N afatinib dimaleate Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 USNRYVNRPYXCSP-JUGPPOIOSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229960001372 aprepitant Drugs 0.000 description 2
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 2
- 229960001215 bendamustine hydrochloride Drugs 0.000 description 2
- 229960002938 bexarotene Drugs 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- 229940031416 bivalent vaccine Drugs 0.000 description 2
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 235000008207 calcium folinate Nutrition 0.000 description 2
- 239000011687 calcium folinate Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229960005061 crizotinib Drugs 0.000 description 2
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 229940094488 cytarabine liposome Drugs 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 229960003603 decitabine Drugs 0.000 description 2
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 2
- 230000003831 deregulation Effects 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960004102 dexrazoxane hydrochloride Drugs 0.000 description 2
- BIFMNMPSIYHKDN-FJXQXJEOSA-N dexrazoxane hydrochloride Chemical compound [H+].[Cl-].C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BIFMNMPSIYHKDN-FJXQXJEOSA-N 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 2
- 229960000452 diethylstilbestrol Drugs 0.000 description 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 2
- CKQQMPJQZXIYMJ-UHFFFAOYSA-N dihydrate;dihydrochloride Chemical compound O.O.Cl.Cl CKQQMPJQZXIYMJ-UHFFFAOYSA-N 0.000 description 2
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 2
- 229960004199 dutasteride Drugs 0.000 description 2
- 229940121647 egfr inhibitor Drugs 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 229960004671 enzalutamide Drugs 0.000 description 2
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229960003265 epirubicin hydrochloride Drugs 0.000 description 2
- 208000037828 epithelial carcinoma Diseases 0.000 description 2
- 229960005073 erlotinib hydrochloride Drugs 0.000 description 2
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 description 2
- 229960002568 ethinylestradiol Drugs 0.000 description 2
- 229960000255 exemestane Drugs 0.000 description 2
- 229960005304 fludarabine phosphate Drugs 0.000 description 2
- 229960002258 fulvestrant Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960005144 gemcitabine hydrochloride Drugs 0.000 description 2
- 239000002748 glycoprotein P inhibitor Substances 0.000 description 2
- 229960003690 goserelin acetate Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000025750 heavy chain disease Diseases 0.000 description 2
- 201000002222 hemangioblastoma Diseases 0.000 description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 230000002267 hypothalamic effect Effects 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- 229960001176 idarubicin hydrochloride Drugs 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 229960003685 imatinib mesylate Drugs 0.000 description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
- 229960002751 imiquimod Drugs 0.000 description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 229960002014 ixabepilone Drugs 0.000 description 2
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 2
- 108010021336 lanreotide Proteins 0.000 description 2
- 229960001739 lanreotide acetate Drugs 0.000 description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 206010024627 liposarcoma Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 229960002247 lomustine Drugs 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 229940124302 mTOR inhibitor Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 2
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 2
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
- 229960002514 melphalan hydrochloride Drugs 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 2
- 229960004169 mitoxantrone hydrochloride Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229940014456 mycophenolate Drugs 0.000 description 2
- 208000001611 myxosarcoma Diseases 0.000 description 2
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 2
- 229960000801 nelarabine Drugs 0.000 description 2
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 208000008795 neuromyelitis optica Diseases 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 229960002700 octreotide Drugs 0.000 description 2
- 229960000572 olaparib Drugs 0.000 description 2
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 2
- 229960000770 ondansetron hydrochloride Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 2
- 201000010198 papillary carcinoma Diseases 0.000 description 2
- MQHIQUBXFFAOMK-UHFFFAOYSA-N pazopanib hydrochloride Chemical compound Cl.C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 MQHIQUBXFFAOMK-UHFFFAOYSA-N 0.000 description 2
- 229960005492 pazopanib hydrochloride Drugs 0.000 description 2
- 229960003349 pemetrexed disodium Drugs 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 208000024724 pineal body neoplasm Diseases 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229960000688 pomalidomide Drugs 0.000 description 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 2
- 229960004197 prasugrel Drugs 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 239000003197 protein kinase B inhibitor Substances 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 201000010174 renal carcinoma Diseases 0.000 description 2
- 201000010384 renal tubular acidosis Diseases 0.000 description 2
- 229960000215 ruxolitinib Drugs 0.000 description 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 2
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 201000008261 skin carcinoma Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960000487 sorafenib tosylate Drugs 0.000 description 2
- IVDHYUQIDRJSTI-UHFFFAOYSA-N sorafenib tosylate Chemical compound [H+].CC1=CC=C(S([O-])(=O)=O)C=C1.C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 IVDHYUQIDRJSTI-UHFFFAOYSA-N 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 201000010965 sweat gland carcinoma Diseases 0.000 description 2
- 201000008753 synovium neoplasm Diseases 0.000 description 2
- 229960001967 tacrolimus Drugs 0.000 description 2
- 229950010924 talaporfin Drugs 0.000 description 2
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 2
- 229960003454 tamoxifen citrate Drugs 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 206010043207 temporal arteritis Diseases 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 229960001712 testosterone propionate Drugs 0.000 description 2
- 229940031351 tetravalent vaccine Drugs 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 229960002190 topotecan hydrochloride Drugs 0.000 description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
- 229960005026 toremifene Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
- 229960000604 valproic acid Drugs 0.000 description 2
- 229960000653 valrubicin Drugs 0.000 description 2
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 229960004276 zoledronic acid Drugs 0.000 description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
- YKJYKKNCCRKFSL-RDBSUJKOSA-N (-)-anisomycin Chemical compound C1=CC(OC)=CC=C1C[C@@H]1[C@H](OC(C)=O)[C@@H](O)CN1 YKJYKKNCCRKFSL-RDBSUJKOSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 1
- QBADKJRRVGKRHP-JLXQGRKUSA-N (3as)-2-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3h-benzo[de]isoquinolin-1-one;2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethyl-n-[6-(4-methylpiperazin-1-yl)-4-[(3z)-penta-1,3-dien-3-yl]pyridin-3-yl]propanamide Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1.C\C=C(\C=C)C1=CC(N2CCN(C)CC2)=NC=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 QBADKJRRVGKRHP-JLXQGRKUSA-N 0.000 description 1
- GDFGTRDCCWFXTG-SCTDSRPQSA-N (3r,4ar,10as)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2h-benzo[g]quinoline Chemical compound C1=CC=C2C[C@@H]3N(CCC)C[C@H](NS(=O)(=O)N(CC)CC)C[C@H]3CC2=C1O GDFGTRDCCWFXTG-SCTDSRPQSA-N 0.000 description 1
- IFGIYSGOEZJNBE-LHJYHSJWSA-N (3s,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one;bromide Chemical compound [Br-].C([N@@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 IFGIYSGOEZJNBE-LHJYHSJWSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- KSJVAYBCXSURMQ-UHFFFAOYSA-N 1-(3-chloro-4-methylphenyl)-3-[2,6-dinitro-4-(trifluoromethyl)anilino]thiourea Chemical compound C1=C(Cl)C(C)=CC=C1NC(=S)NNC1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O KSJVAYBCXSURMQ-UHFFFAOYSA-N 0.000 description 1
- JBSWLQWGIZUKCI-UHFFFAOYSA-N 1-benzyl-1-methylhydrazine;hydrochloride Chemical compound Cl.CN(N)CC1=CC=CC=C1 JBSWLQWGIZUKCI-UHFFFAOYSA-N 0.000 description 1
- HDCUSMZVZWLDRZ-UHFFFAOYSA-N 1-benzyl-2-methylhydrazine Chemical compound CNNCC1=CC=CC=C1 HDCUSMZVZWLDRZ-UHFFFAOYSA-N 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-O 2-(2,4-difluorophenyl)-1-(1h-1,2,4-triazol-2-ium-2-yl)-3-(1,2,4-triazol-1-yl)propan-2-ol Chemical compound C([C@](O)(C[N+]=1NC=NC=1)C=1C(=CC(F)=CC=1)F)N1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-O 0.000 description 1
- KHZOJCQBHJUJFY-UHFFFAOYSA-N 2-[4-(2-methylpyridin-4-yl)phenyl]-n-(4-pyridin-3-ylphenyl)acetamide Chemical compound C1=NC(C)=CC(C=2C=CC(CC(=O)NC=3C=CC(=CC=3)C=3C=NC=CC=3)=CC=2)=C1 KHZOJCQBHJUJFY-UHFFFAOYSA-N 0.000 description 1
- KVQOGDQTWWCZFX-UHFFFAOYSA-N 2-[[3-[[2-(dimethylamino)phenyl]methyl]-2-pyridin-4-yl-1,3-diazinan-1-yl]methyl]-N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1CN1C(C=2C=CN=CC=2)N(CC=2C(=CC=CC=2)N(C)C)CCC1 KVQOGDQTWWCZFX-UHFFFAOYSA-N 0.000 description 1
- UYJNQQDJUOUFQJ-UHFFFAOYSA-N 2-[[5-chloro-2-[2-methoxy-4-(4-morpholinyl)anilino]-4-pyrimidinyl]amino]-N-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(=CC=2)N2CCOCC2)OC)=NC=C1Cl UYJNQQDJUOUFQJ-UHFFFAOYSA-N 0.000 description 1
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 description 1
- ZGXOBLVQIVXKEB-UHFFFAOYSA-N 3-[N-[3-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-N,N-dimethyl-1H-indole-6-carboxamide Chemical compound CN(C)CC1=CC(=CC=C1)N=C(C2=CC=CC=C2)C3=C(NC4=C3C=CC(=C4)C(=O)N(C)C)O ZGXOBLVQIVXKEB-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- PRRZDZJYSJLDBS-UHFFFAOYSA-N 3-bromo-2-oxopropanoic acid Chemical compound OC(=O)C(=O)CBr PRRZDZJYSJLDBS-UHFFFAOYSA-N 0.000 description 1
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 1
- ZKEZEXYKYHYIMQ-UHFFFAOYSA-N 3-cyclohexyl-1-(2-morpholin-4-yl-2-oxoethyl)-2-phenyl-1h-indole-6-carboxylic acid Chemical compound C=1C=CC=CC=1C=1N(CC(=O)N2CCOCC2)C2=CC(C(=O)O)=CC=C2C=1C1CCCCC1 ZKEZEXYKYHYIMQ-UHFFFAOYSA-N 0.000 description 1
- 108010039636 3-isopropylmalate dehydrogenase Proteins 0.000 description 1
- RYQOILLJDKPETL-UHFFFAOYSA-N 5-aminolevulinic acid hexyl ester Chemical compound CCCCCCOC(=O)CCC(=O)CN RYQOILLJDKPETL-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 description 1
- 239000005660 Abamectin Substances 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- TWHZNAUBXFZMCA-UHFFFAOYSA-N Acotiamide Chemical compound C1=C(OC)C(OC)=CC(O)=C1C(=O)NC1=NC(C(=O)NCCN(C(C)C)C(C)C)=CS1 TWHZNAUBXFZMCA-UHFFFAOYSA-N 0.000 description 1
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 229940123407 Androgen receptor antagonist Drugs 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- YKJYKKNCCRKFSL-UHFFFAOYSA-N Anisomycin Natural products C1=CC(OC)=CC=C1CC1C(OC(C)=O)C(O)CN1 YKJYKKNCCRKFSL-UHFFFAOYSA-N 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 206010060971 Astrocytoma malignant Diseases 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 201000008271 Atypical teratoid rhabdoid tumor Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 description 1
- 206010069002 Autoimmune pancreatitis Diseases 0.000 description 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 108091005625 BRD4 Proteins 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 101150072730 Bmp6 gene Proteins 0.000 description 1
- 101710154297 Bromodomain testis-specific protein Proteins 0.000 description 1
- 102100033641 Bromodomain-containing protein 2 Human genes 0.000 description 1
- 102100033642 Bromodomain-containing protein 3 Human genes 0.000 description 1
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 1
- 108091005575 Bromodomain-containing proteins Proteins 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- LQSPYTDDQJPNCW-UHFFFAOYSA-N C(CCCCCC)[Pt] Chemical compound C(CCCCCC)[Pt] LQSPYTDDQJPNCW-UHFFFAOYSA-N 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
- 102100028681 C-type lectin domain family 4 member K Human genes 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 239000005746 Carboxin Substances 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- 229940122360 Casein kinase 2 inhibitor Drugs 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 108010017573 Ceramide kinase Proteins 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000010007 Cogan syndrome Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011258 Coxsackie myocarditis Diseases 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- 229910000570 Cupronickel Inorganic materials 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 230000000970 DNA cross-linking effect Effects 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 239000012625 DNA intercalator Substances 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 description 1
- 206010064581 Desmoplastic small round cell tumour Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 208000021866 Dressler syndrome Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 1
- 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 description 1
- 102100039248 Elongation of very long chain fatty acids protein 7 Human genes 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 102100036895 Exocyst complex component 3-like protein 4 Human genes 0.000 description 1
- 229940124783 FAK inhibitor Drugs 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 239000005562 Glyphosate Substances 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 102100028538 Guanylate-binding protein 4 Human genes 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 101000794028 Homo sapiens Bromodomain testis-specific protein Proteins 0.000 description 1
- 101000871850 Homo sapiens Bromodomain-containing protein 2 Proteins 0.000 description 1
- 101000871851 Homo sapiens Bromodomain-containing protein 3 Proteins 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 1
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
- 101000766965 Homo sapiens C-type lectin domain family 4 member K Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000715711 Homo sapiens Ceramide kinase Proteins 0.000 description 1
- 101000813103 Homo sapiens Elongation of very long chain fatty acids protein 7 Proteins 0.000 description 1
- 101000851449 Homo sapiens Exocyst complex component 3-like protein 4 Proteins 0.000 description 1
- 101001058851 Homo sapiens Guanylate-binding protein 4 Proteins 0.000 description 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101000972286 Homo sapiens Mucin-4 Proteins 0.000 description 1
- 101001033058 Homo sapiens Probable G-protein coupled receptor 88 Proteins 0.000 description 1
- 101000585728 Homo sapiens Protein O-GlcNAcase Proteins 0.000 description 1
- 101001123986 Homo sapiens Protein-serine O-palmitoleoyltransferase porcupine Proteins 0.000 description 1
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 1
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 101001074042 Homo sapiens Transcriptional activator GLI3 Proteins 0.000 description 1
- 101000764634 Homo sapiens Transmembrane gamma-carboxyglutamic acid protein 4 Proteins 0.000 description 1
- 101000798165 Homo sapiens Trichohyalin Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000638255 Homo sapiens Tumor necrosis factor ligand superfamily member 8 Proteins 0.000 description 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 1
- 102000003918 Hyaluronan Synthases Human genes 0.000 description 1
- 108090000320 Hyaluronan Synthases Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- VDJHFHXMUKFKET-UHFFFAOYSA-N Ingenol mebutate Natural products CC1CC2C(C)(C)C2C2C=C(CO)C(O)C3(O)C(OC(=O)C(C)=CC)C(C)=CC31C2=O VDJHFHXMUKFKET-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- YMFNPBSZFWXMAD-UHFFFAOYSA-N JSH-23 Chemical compound NC1=CC(C)=CC=C1NCCCC1=CC=CC=C1 YMFNPBSZFWXMAD-UHFFFAOYSA-N 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- LAZPBGZRMVRFKY-HNCPQSOCSA-N Levamisole hydrochloride Chemical compound Cl.C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 LAZPBGZRMVRFKY-HNCPQSOCSA-N 0.000 description 1
- 206010024434 Lichen sclerosus Diseases 0.000 description 1
- 208000012309 Linear IgA disease Diseases 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 239000012820 MEK1 Inhibitor Substances 0.000 description 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
- 102100022693 Mucin-4 Human genes 0.000 description 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 description 1
- 101100408855 Mus musculus Porcn gene Proteins 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- AFJRDFWMXUECEW-LBPRGKRZSA-N N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methyl-3-pyrazolyl)-2-thiophenecarboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)SC(C(=O)N[C@H](CN)CC=2C=C(F)C=CC=2)=C1 AFJRDFWMXUECEW-LBPRGKRZSA-N 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 206010028767 Nasal sinus cancer Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010071579 Neuronal neuropathy Diseases 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 description 1
- 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 1
- 241001420836 Ophthalmitis Species 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010033268 Ovarian low malignant potential tumour Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 239000012271 PD-L1 inhibitor Substances 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000003937 Paranasal Sinus Neoplasms Diseases 0.000 description 1
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034665 Peritoneal fibrosis Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
- 206010050487 Pinealoblastoma Diseases 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 208000000766 Pityriasis Lichenoides Diseases 0.000 description 1
- 206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000031732 Post-Lyme Disease Syndrome Diseases 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 102100038404 Probable G-protein coupled receptor 88 Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102100028119 Protein-serine O-palmitoleoyltransferase porcupine Human genes 0.000 description 1
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 201000008183 Pulmonary blastoma Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 102000034527 Retinoid X Receptors Human genes 0.000 description 1
- 108010038912 Retinoid X Receptors Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- HDAJDNHIBCDLQF-RUZDIDTESA-N SCH772984 Chemical compound O=C([C@@H]1CCN(C1)CC(=O)N1CCN(CC1)C=1C=CC(=CC=1)C=1N=CC=CN=1)NC(C=C12)=CC=C1NN=C2C1=CC=NC=C1 HDAJDNHIBCDLQF-RUZDIDTESA-N 0.000 description 1
- 238000004741 STD-NMR spectroscopy Methods 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 102100023921 Serine/threonine-protein kinase ATR Human genes 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042276 Subacute endocarditis Diseases 0.000 description 1
- 208000002286 Susac Syndrome Diseases 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- 208000000728 Thymus Neoplasms Diseases 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- 206010051526 Tolosa-Hunt syndrome Diseases 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 102100035559 Transcriptional activator GLI3 Human genes 0.000 description 1
- 102100026222 Transmembrane gamma-carboxyglutamic acid protein 4 Human genes 0.000 description 1
- 102100032250 Trichohyalin Human genes 0.000 description 1
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 1
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- ZSTCHQOKNUXHLZ-PIRIXANTSA-L [(1r,2r)-2-azanidylcyclohexyl]azanide;oxalate;pentyl n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate;platinum(4+) Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@@H]1CCCC[C@H]1[NH-].C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 ZSTCHQOKNUXHLZ-PIRIXANTSA-L 0.000 description 1
- RDNJGIAWTAMGGM-UPIZIACDSA-N [(6s,8r,9s,10r,13s,14s,17r)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] hexanoate Chemical compound C1([C@@H](C)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]2(C)CC1 RDNJGIAWTAMGGM-UPIZIACDSA-N 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- 229960002184 abarelix Drugs 0.000 description 1
- 108010023617 abarelix Proteins 0.000 description 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
- 229950008805 abexinostat Drugs 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229950005462 acotiamide Drugs 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 229950000079 afuresertib Drugs 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960003235 allopurinol sodium Drugs 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229960000781 aminolevulinic acid hydrochloride Drugs 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 239000003936 androgen receptor antagonist Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 229960001164 apremilast Drugs 0.000 description 1
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 208000027625 autoimmune inner ear disease Diseases 0.000 description 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 description 1
- 206010071578 autoimmune retinopathy Diseases 0.000 description 1
- 208000029407 autoimmune urticaria Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 1
- 229950009579 axicabtagene ciloleucel Drugs 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- UCJGJABZCDBEDK-UHFFFAOYSA-N bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 description 1
- 229960000817 bazedoxifene Drugs 0.000 description 1
- FUKOGSUFTZDYOI-BMANNDLBSA-O beacopp protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.CNNCC1=CC=C(C(=O)NC(C)C)C=C1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)C(O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C FUKOGSUFTZDYOI-BMANNDLBSA-O 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 229950000080 birabresib Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229960004395 bleomycin sulfate Drugs 0.000 description 1
- 201000004571 bone carcinoma Diseases 0.000 description 1
- 208000012172 borderline epithelial tumor of ovary Diseases 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 229960001169 brivudine Drugs 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 1
- 229960001573 cabazitaxel Drugs 0.000 description 1
- 108010033937 calaspargase pegol Proteins 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 229960001921 calcium levofolinate Drugs 0.000 description 1
- KVUAALJSMIVURS-QNTKWALQSA-L calcium;(2s)-2-[[4-[[(6s)-2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioate Chemical compound [Ca+2].C([C@@H]1N(C=O)C=2C(=O)N=C(NC=2NC1)N)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-QNTKWALQSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 229960004399 carbocisteine Drugs 0.000 description 1
- IQXIUTMSTALSFW-VJFOLWCZSA-N carboplatin paclitaxel Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 IQXIUTMSTALSFW-VJFOLWCZSA-N 0.000 description 1
- GYSSRZJIHXQEHQ-UHFFFAOYSA-N carboxin Chemical compound S1CCOC(C)=C1C(=O)NC1=CC=CC=C1 GYSSRZJIHXQEHQ-UHFFFAOYSA-N 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- YMNCVRSYJBNGLD-KURKYZTESA-N cephalotaxine Chemical compound C([C@@]12C=C([C@H]([C@H]2C2=C3)O)OC)CCN1CCC2=CC1=C3OCO1 YMNCVRSYJBNGLD-KURKYZTESA-N 0.000 description 1
- DSRNKUZOWRFQFO-UHFFFAOYSA-N cephalotaxine Natural products COC1=CC23CCCN2CCc4cc5OCOc5cc4C3=C1O DSRNKUZOWRFQFO-UHFFFAOYSA-N 0.000 description 1
- 201000007335 cerebellar astrocytoma Diseases 0.000 description 1
- 208000030239 cerebral astrocytoma Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- HJKBJIYDJLVSAO-UHFFFAOYSA-L clodronic acid disodium salt Chemical compound [Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O HJKBJIYDJLVSAO-UHFFFAOYSA-L 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- IMBXRZKCLVBLBH-OGYJWPHRSA-N cvp protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 IMBXRZKCLVBLBH-OGYJWPHRSA-N 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
- 229960002427 dabrafenib mesylate Drugs 0.000 description 1
- 229960003109 daunorubicin hydrochloride Drugs 0.000 description 1
- 229960004120 defibrotide Drugs 0.000 description 1
- 229960002272 degarelix Drugs 0.000 description 1
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 description 1
- 238000007416 differential thermogravimetric analysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 230000000408 embryogenic effect Effects 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002159 estradiols Chemical class 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- QPUSANCBJDDXSA-UHFFFAOYSA-N ethanethiol;sodium Chemical compound [Na].CCS QPUSANCBJDDXSA-UHFFFAOYSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- 229940081995 fluorouracil injection Drugs 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- PJZDLZXMGBOJRF-CXOZILEQSA-L folfirinox Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@H]1CCCC[C@@H]1[NH-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 PJZDLZXMGBOJRF-CXOZILEQSA-L 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- BARDROPHSZEBKC-OITMNORJSA-N fosaprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NC(=O)N(P(O)(O)=O)N1 BARDROPHSZEBKC-OITMNORJSA-N 0.000 description 1
- 229960002891 fosaprepitant Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 208000018090 giant cell myocarditis Diseases 0.000 description 1
- 229940097068 glyphosate Drugs 0.000 description 1
- XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- 229960003607 granisetron hydrochloride Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 229940097293 hexyl 5-aminolevulinate Drugs 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 229960003911 histrelin acetate Drugs 0.000 description 1
- BKEMVGVBBDMHKL-VYFXDUNUSA-N histrelin acetate Chemical compound CC(O)=O.CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 BKEMVGVBBDMHKL-VYFXDUNUSA-N 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 102000046319 human OGA Human genes 0.000 description 1
- 229940101556 human hyaluronidase Drugs 0.000 description 1
- QYZRTBKYBJRGJB-UHFFFAOYSA-N hydron;1-methyl-n-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)indazole-3-carboxamide;chloride Chemical compound Cl.C1=CC=C2C(C(=O)NC3CC4CCCC(C3)N4C)=NN(C)C2=C1 QYZRTBKYBJRGJB-UHFFFAOYSA-N 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- VDJHFHXMUKFKET-WDUFCVPESA-N ingenol mebutate Chemical compound C[C@@H]1C[C@H]2C(C)(C)[C@H]2[C@@H]2C=C(CO)[C@@H](O)[C@]3(O)[C@@H](OC(=O)C(\C)=C/C)C(C)=C[C@]31C2=O VDJHFHXMUKFKET-WDUFCVPESA-N 0.000 description 1
- 229960002993 ingenol mebutate Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 229940048117 irinotecan hydrochloride liposome Drugs 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 201000002529 islet cell tumor Diseases 0.000 description 1
- 229960005435 ixekizumab Drugs 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 229960001320 lapatinib ditosylate Drugs 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 229960002367 lasofoxifene Drugs 0.000 description 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960001429 lenvatinib mesylate Drugs 0.000 description 1
- HWLFIUUAYLEFCT-UHFFFAOYSA-N lenvatinib mesylate Chemical compound CS(O)(=O)=O.C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 HWLFIUUAYLEFCT-UHFFFAOYSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 229960003734 levamisole hydrochloride Drugs 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229950008991 lobaplatin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- OHSVLFRHMCKCQY-NJFSPNSNSA-N lutetium-177 Chemical compound [177Lu] OHSVLFRHMCKCQY-NJFSPNSNSA-N 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 201000003175 male breast cancer Diseases 0.000 description 1
- 208000010907 male breast carcinoma Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 208000030883 malignant astrocytoma Diseases 0.000 description 1
- 208000016848 malignant germ cell tumor Diseases 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960002868 mechlorethamine hydrochloride Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037970 metastatic squamous neck cancer Diseases 0.000 description 1
- YUUAYBAIHCDHHD-UHFFFAOYSA-N methyl 5-aminolevulinate Chemical compound COC(=O)CCC(=O)CN YUUAYBAIHCDHHD-UHFFFAOYSA-N 0.000 description 1
- 229960005033 methyl aminolevulinate Drugs 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960002834 methylnaltrexone bromide Drugs 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 206010063344 microscopic polyangiitis Diseases 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 229950010895 midostaurin Drugs 0.000 description 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 230000006618 mitotic catastrophe Effects 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 description 1
- 229950000720 moxetumomab pasudotox Drugs 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- AZBFJBJXUQUQLF-UHFFFAOYSA-N n-(1,5-dimethylpyrrolidin-3-yl)pyrrolidine-1-carboxamide Chemical compound C1N(C)C(C)CC1NC(=O)N1CCCC1 AZBFJBJXUQUQLF-UHFFFAOYSA-N 0.000 description 1
- MVSSJPGNLQPWSW-UHFFFAOYSA-N n-(2-benzamido-1,3-benzothiazol-6-yl)adamantane-1-carboxamide Chemical compound N=1C2=CC=C(NC(=O)C34CC5CC(CC(C5)C3)C4)C=C2SC=1NC(=O)C1=CC=CC=C1 MVSSJPGNLQPWSW-UHFFFAOYSA-N 0.000 description 1
- YFQJOPFTGMHYNV-YDALLXLXSA-N n-[(2s)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)thiophene-2-carboxamide;hydrochloride Chemical compound Cl.CN1N=CC(Cl)=C1C1=C(Cl)SC(C(=O)N[C@H](CN)CC=2C=C(F)C=CC=2)=C1 YFQJOPFTGMHYNV-YDALLXLXSA-N 0.000 description 1
- HRDQQHUKUIKFHT-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-methyl-6-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-1-propan-2-ylindole-4-carboxamide Chemical compound C1=C2N(C(C)C)C=C(C)C2=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C=C1C(C=N1)=CC=C1N1CCN(C)CC1 HRDQQHUKUIKFHT-UHFFFAOYSA-N 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 208000037830 nasal cancer Diseases 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 229940053050 neomycin sulfate Drugs 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- WAXQNWCZJDTGBU-UHFFFAOYSA-N netupitant Chemical compound C=1N=C(N2CCN(C)CC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WAXQNWCZJDTGBU-UHFFFAOYSA-N 0.000 description 1
- 229960005163 netupitant Drugs 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 201000008859 olfactory neuroblastoma Diseases 0.000 description 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- KGCNHWXDPDPSBV-UHFFFAOYSA-N p-nitrobenzyl chloride Chemical compound [O-][N+](=O)C1=CC=C(CCl)C=C1 KGCNHWXDPDPSBV-UHFFFAOYSA-N 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 208000021010 pancreatic neuroendocrine tumor Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 208000010403 panophthalmitis Diseases 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000029211 papillomatosis Diseases 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
- 229960003634 pimozide Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229940126167 polatuzumab vedotin-piiq Drugs 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000008741 proinflammatory signaling process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol hydrochloride Natural products C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 229960004604 propranolol hydrochloride Drugs 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000006825 purine synthesis Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 229960000924 quinagolide Drugs 0.000 description 1
- 239000002534 radiation-sensitizing agent Substances 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- RWRDJVNMSZYMDV-UHFFFAOYSA-L radium chloride Chemical compound [Cl-].[Cl-].[Ra+2] RWRDJVNMSZYMDV-UHFFFAOYSA-L 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical compound [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 description 1
- 229960002119 raloxifene hydrochloride Drugs 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 1
- 108010091666 romidepsin Proteins 0.000 description 1
- 229940116736 romycin Drugs 0.000 description 1
- 229960002539 ruxolitinib phosphate Drugs 0.000 description 1
- JFMWPOCYMYGEDM-XFULWGLBSA-N ruxolitinib phosphate Chemical compound OP(O)(O)=O.C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 JFMWPOCYMYGEDM-XFULWGLBSA-N 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 229960004540 secukinumab Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960000714 sipuleucel-t Drugs 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- PTJRZVJXXNYNLN-UHFFFAOYSA-M sodium;2h-pyrazolo[3,4-d]pyrimidin-1-id-4-one Chemical compound [Na+].[O-]C1=NC=NC2=C1C=NN2 PTJRZVJXXNYNLN-UHFFFAOYSA-M 0.000 description 1
- PISVIEQBTMLLCS-UHFFFAOYSA-M sodium;ethyl-oxido-oxo-sulfanylidene-$l^{6}-sulfane Chemical compound [Na+].CCS([O-])(=O)=S PISVIEQBTMLLCS-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 208000008467 subacute bacterial endocarditis Diseases 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 229960002812 sunitinib malate Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 108091003260 tagraxofusp Proteins 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229950010130 tamibarotene Drugs 0.000 description 1
- MUTNCGKQJGXKEM-UHFFFAOYSA-N tamibarotene Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=C(C(O)=O)C=C1 MUTNCGKQJGXKEM-UHFFFAOYSA-N 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 229960000331 teriflunomide Drugs 0.000 description 1
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- 150000008634 thiazolopyrimidines Chemical class 0.000 description 1
- JOUDBUYBGJYFFP-FOCLMDBBSA-N thioindigo Chemical compound S\1C2=CC=CC=C2C(=O)C/1=C1/C(=O)C2=CC=CC=C2S1 JOUDBUYBGJYFFP-FOCLMDBBSA-N 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 201000009377 thymus cancer Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 1
- 229960000977 trabectedin Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- LFOHPKKMDYSRLY-UHFFFAOYSA-N uridine triacetate Natural products CC(=O)OCC1OC(CN2C=CC(=O)NC2=O)C(OC(=O)C)C1OC(=O)C LFOHPKKMDYSRLY-UHFFFAOYSA-N 0.000 description 1
- AUFUWRKPQLGTGF-FMKGYKFTSA-N uridine triacetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1N1C(=O)NC(=O)C=C1 AUFUWRKPQLGTGF-FMKGYKFTSA-N 0.000 description 1
- 229960003498 uridine triacetate Drugs 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- ATCJTYORYKLVIA-SRXJVYAUSA-N vamp regimen Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 ATCJTYORYKLVIA-SRXJVYAUSA-N 0.000 description 1
- 229960004914 vedolizumab Drugs 0.000 description 1
- 229960003895 verteporfin Drugs 0.000 description 1
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 1
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
- 229960004982 vinblastine sulfate Drugs 0.000 description 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
- 229960002110 vincristine sulfate Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000004400 visual pathway Effects 0.000 description 1
- 210000000239 visual pathway Anatomy 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了结晶5‑(二甲基氨基)‑N‑(4‑(吗啉代甲基)苯基)萘‑1‑磺酰胺二盐酸盐二水合物、制备所述结晶盐的方法、含有所述结晶盐的药物组合物以及使用所述结晶盐的治疗方法。
Description
本申请根据35U.S.C.§119(e)要求于2020年10月29日提交的美国临时申请号63/106,991的权益,其通过援引以其全文并入。
技术领域
本发明涉及结晶5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐二水合物、制备该结晶盐的方法、含有该结晶盐的药物组合物以及使用该结晶盐的治疗方法。
背景技术
丝裂原活化蛋白激酶(MAPK)是处理和调节对广泛的细胞外刺激有应答的细胞特性的丝氨酸/苏氨酸蛋白激酶。这些酶使蛋白质中丝氨酸或苏氨酸的OH基团磷酸化,并在细胞增殖、分化、存活和凋亡的调节中发挥重要作用。在哺乳动物细胞中,已经鉴定出几种不同的MAPK,包括p38 MAPK。
p38 MAPK是一类应答诸如炎症细胞因子和活性氧(ROS)的应激刺激的MAPK,并且参与广泛的刺激不同生物功能的信号传导通路。例如,p38 MAPK在促炎信号传导网络的调节和细胞因子(包括免疫细胞中的肿瘤坏死因子-α(TNF-α)和白介素-1β(IL-1β))的生物合成中起着重要作用。
研究显示p38 MAPK促成慢性炎症的发病机制,这已引起对用于治疗诸如类风湿性关节炎和哮喘的炎性疾病的p38 MAPK抑制剂的鉴定和开发。
p38 MAPK包含四种同种型(α、β、γ和δ)。p38αMAPK是第一个被鉴定的p38 MAPK同种型,并且最先被认为是可以被脂多糖(LPS)和炎性细胞因子活化的应激诱导激酶。抑制p38 MAPK已显示有效缓解诸如类风湿性关节炎、心血管疾病和炎性疼痛的炎性疾病。
许多p38 MAPK催化抑制剂效果不佳并会引起毒性,这可能是由于对非炎性p38的活性和p38α依赖性反调节应答的丧失。期望可以选择性阻断某些p38αMAPK功能并保持关键的反调节和稳态功能的用于治疗炎性和肿瘤疾病的p38αMAPK抑制剂。
发明内容
根据本发明,化合物为结晶5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐二水合物:
根据本发明,药物组合物包含化合物(1)。
根据本发明,治疗患者的疾病的方法包括向需要此类治疗的患者施用治疗有效量的化合物(1),其中该疾病是癌症。
根据本发明,治疗患者的疾病的方法包括向需要此类治疗的患者施用治疗有效量的化合物(1),其中该疾病是炎性疾病。
根据本发明,治疗患者的疾病的方法包括向需要此类治疗的患者施用治疗有效量的化合物(1),其中该疾病是自身免疫性疾病。
根据本发明,治疗患者的疾病的方法包括向需要此类治疗的患者施用治疗有效量的化合物(1),其中该疾病是年龄相关性疾病。
根据本发明,治疗患者的疾病的方法包括向需要此类治疗的患者施用治疗有效量的化合物(1),其中该疾病选自急性肺损伤、急性呼吸窘迫综合征(ARDS)和慢性阻塞性肺病(COPD)。
根据本发明,抑制p38αMAPK受体的方法包括使p38αMAPK受体与化合物(1)接触。
根据本发明,抑制患者的p38αMAPK受体的方法包括向患者施用药理学有效量的化合物(1)。
附图说明
本文描述的附图仅出于说明的目的。附图不旨在限制本公开的范围。
图1示出了结晶5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐二水合物(化合物(1))的X射线粉末衍射(XRPD)图案。
图2示出了化合物(1)的差示扫描量热法(DSC)扫描。
图3示出了化合物(1)在2℃/min的扫描速率下的热重分析(TGA)扫描。
图4示出了化合物(1)在4℃/min的扫描速率下的热重分析(TGA)扫描。
图5示出了结晶的无水5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐的X射线粉末衍射(XRPD)图案。
图6示出了通过将结晶的无水5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐暴露于大气湿度制备的结晶5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐一水合物的X射线粉末衍射(XRPD)图案。
图7示出了结晶的无水5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐的差示扫描量热法(DSC)扫描。
图8示出了通过将结晶的无水5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐暴露于大气湿度制备的结晶5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐一水合物的热重分析(TGA)扫描。
图9和图10示出了结晶5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐二水合物的三维晶体结构。
具体实施方式
现出于以下详细描述的目的,应当理解,除非明确相反地指出,否则本公开提供的实施例可以采取各种替代性变型和步骤顺序。此外,除了在任何操作实例中或在另有指示的情况下以外,表达例如本说明书和权利要求中所使用的成分的数量的所有数字应被理解为在所有情况下均由术语“约”修饰。因此,除非有相反指示,否则以下说明书和所附权利要求中列出的数字参数是近似值,其可根据本发明获得的所需性质而变化。至少,并且不试图将等效原则的应用限制于权利要求的范围,每个数值参数至少应按照所报告的有效数字的数量并通过应用普通的舍入技术来解释。
尽管阐述本发明的广泛范围的数值范围和参数是近似值,但是具体实例中阐述的数值是尽可能精确地报告的。然而,任何数值固有地包含由在它们各自的测试测量中发现的标准偏差必然产生的某些误差。
此外,应当理解,本文所述的任何数值范围旨在包含其中包含的所有子范围。例如,“1至10”的范围旨在包含介于(和包含)所叙述的最小值1与所叙述的最大值10之间的所有子范围,也就是说,具有等于或大于1的最小值和等于或小于10的最大值。
本文公开的“化合物”和部分包括公开的式内的任何具体化合物。化合物可以通过化学结构和/或通过化学名称来鉴定。使用ChemDraw Professional 17.1.0.105(19)(PerkinElmer Informatics,Inc.)命名程序命名化合物。当化学结构和化学名称冲突时,化学结构决定化合物的身份。本文所述的化合物可包含一个或多个立体中心和/或双键,并且因此可作为立体异构体存在,诸如双键异构体(即几何异构体)、对映异构体、非对映异构体或阻转异构体。因此,说明书范围内全部或部分描述的具有相对构型的任何化学结构涵盖所示化合物的所有可能的对映异构体和立体异构体,包括立体异构纯形式(例如,几何纯、对映体纯或非对映体纯)以及对映异构体和立体异构体的混合物。对映异构体和立体异构体的混合物可以使用本领域的技术人员熟知的分离技术或手性合成技术拆分成其组分对映异构体或立体异构体。
本文所公开的化合物和部分包括化合物和部分的光学异构体、其外消旋体及其其他混合物。在此类实施例中,单一对映异构体或非对映异构体可通过不对称合成或通过外消旋体的拆分获得。外消旋体的拆分可以例如通过常规方法来完成,诸如在拆分剂存在下的结晶或例如使用具有手性固定相的手性高压液相色谱法(HPLC)柱的色谱法。此外,化合物包括作为单一几何异构体或其混合物的具有双键的化合物的(Z)-和(E)形式(或顺式和反式形式)。
化合物和部分还可以以若干互变异构体形式(包括烯醇形式、酮类形式及其混合物)存在。因此,本文所描绘的化学结构涵盖所展示化合物的所有可能的互变异构体形式。化合物可以以非溶剂化形式以及溶剂化形式(包括水合形式)存在。某些化合物可以以多种结晶、共结晶或无定形形式存在。化合物包括其药学上可接受的盐,或任何前述的游离酸形式的药学上可接受的溶剂化物,以及任何前述的结晶形式。
为方便起见,结晶5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐二水合物也称为“结晶二盐酸盐二水合物”或“结晶盐”。
“常释”是指在口服施用后小于1小时内,诸如在口服施用后小于50分钟内、小于40分钟内、小于30分钟内、小于20分钟内或小于10分钟内将基本上所有的药物活性成分释放到患者的胃肠道中的药物组合物。例如,常释剂型可以在口服施用后小于1小时内,诸如在小于50分钟、小于40分钟、小于30分钟、小于20分钟或小于10分钟内将药物组合物中大于90%、大于95%或大于98%的药物活性成分释放到胃肠道中。常释药物组合物可以适于施用从胃肠道的上部被吸收到体循环中的药物活性成分。
“调释”药物组合物包括控制释放制剂、延迟释放制剂、延长释放制剂、持续释放制剂、定时释放制剂、脉冲释放制剂和pH依赖性释放制剂。这些制剂旨在在患者口服施用后以期望的速率和/或在期望的时间和/或在胃肠道内的某个或某些位置和/或在胃肠道内的某个pH下从药物组合物释放药物活性成分。USP将调释系统定义为这样一种系统,在该系统中药物释放的时程或位置或两者被选择以实现常释剂型不能实现的治疗有效性或方便性的目的。调释口服剂型可包括延长释放和延迟释放组分。延迟释放剂型是在施用后一定时间而非立刻一次性释放全部药物的剂型。调释制剂可包括使用肠溶包衣的延迟释放;诸如用于结肠递送的部位特异性或定时释放;包括例如能够提供零级、一级或双相释放概况的制剂的延长释放;以及诸如脉冲和延迟的延长释放的程序释放。
“持续释放”药物组合物和包衣在口服施用后经延长时间段提供溶出速率。包含具有持续释放包衣的小粒的颗粒可称为持续释放颗粒。包含持续释放颗粒的药物组合物可称为持续释放药物组合物。
“pH-释放”药物组合物和包衣在预定pH下提供增加的溶出速率。
“脉冲释放”药物组合物和包衣以一定时间间隔表现出增加的溶出速率,其中释放时间间隔可由时间、暴露于内部刺激或暴露于外部刺激来确定。脉冲释放系统的实例包括胶囊系统、渗透系统、具有可侵蚀膜的系统和具有可破裂包衣的系统。刺激的实例包括温度、化学物质、电刺激和磁刺激。
“定时释放”药物组合物和包衣具有随时间变化的溶出速率。定时释放药物组合物或包衣包括例如延迟释放、持续释放和延长释放药物组合物和包衣。
“延迟释放”药物组合物和包衣在施用之后于预定时间提供增加的溶出速率。
“调节(modulate或modulation)”是指生物分子诸如例如蛋白质、基因、肽或抗体的生物活性的变化,其中此类变化可能涉及生物分子的生物活性的增加(诸如例如活性增加、激动、活化、表达、上调和/或表达增加)或生物分子的生物活性的降低(诸如例如活性降低、拮抗、抑制、失活、下调和/或表达降低)。例如,化合物(2)可以调节p38αMAPK蛋白,诸如抑制p38αMAPK蛋白。与其他MAPK或p38 MAPK蛋白相比,化合物(2)可以选择性地调节,诸如选择性地抑制p38αMAPK蛋白。与其他MAPK或p38 MAPK蛋白相比,化合物(2)可以选择性地调节,诸如选择性地抑制p38αMAPK蛋白。
“部分”是指分子的具体片段或官能团。化学部分通常是嵌入分子内或添加到分子中的公认化学实体。
“患者”是指哺乳动物,例如人。
“药学上可接受的”是指由或可由联邦政府或州政府的监管机构批准的或在美国药典或其它公认的药典中列出的用于动物并且更具体地用于人类。
“药学上可接受的媒剂”是指药学上可接受的稀释剂、药学上可接受的佐剂、药学上可接受的赋形剂、药学上可接受的载体或任何前述的组合,该药学上可接受的媒剂可与本公开提供的化合物一起施用于患者,并且当以足以提供治疗有效量的化合物的剂量施用时,不会破坏其药理活性并且是无毒的。
“药物组合物”是指化合物(1)和至少一种药学上可接受的媒剂,化合物(1)与该药学上可接受的媒剂一起施用于患者。药学上可接受的媒剂是本领域已知的。
“疾病”指任何前述的疾病、病症、病况或症状。
“预防(preventing或prevention)”是指降低患上疾病或病症的风险(即,使至少一种疾病的临床症状不会在可能暴露于或易患该疾病但尚未经历或展示疾病症状的患者中发展)。在一些实施例中,“预防”是指通过以预防方式施用本公开提供的化合物来减轻疾病的症状。应用治疗剂来预防病症的疾病称为“预防”。由于经长时间段的长期副作用较低,本公开提供的化合物可提供优异的预防。
“治愈”疾病是指消除疾病或病症、或者消除疾病或病症的症状。
疾病或病症的“治疗(treating或treatment)”是指抑制疾病或病症、或者疾病或病症的一种或多种临床症状;阻止疾病或病症、或者疾病或病症的一种或多种临床症状的发展;缓解疾病或病症、或者疾病或病症的一种或多种临床症状;引起疾病或病症、或者疾病或病症的一种或多种临床症状的消退;降低疾病或病症的一种或多种临床症状的严重性;延迟疾病或病症的一种或多种临床症状的发作;减轻疾病或病症的一种或多种临床症状;和/或稳定疾病或病症、或疾病或病症的一种或多种临床症状。疾病或病症的“治疗”包括在不治愈潜在疾病或病症的情况下产生临床上有益的作用。
“治疗有效量”是指当施用于患者用于治疗疾病或疾病的至少一种临床症状时,足以影响疾病或其症状的此类治疗的诸如药物活性成分的化合物的量。“治疗有效量”可以根据例如化合物、疾病和/或疾病的症状、疾病的严重性和/或疾病或病症的症状、待治疗患者的年龄、体重和/或健康状况以及开处方医生的判断而变化。在任何给定情况下的治疗有效量可以由本领域技术人员确定或能够通过常规实验确定。
“治疗有效剂量”是指提供对患者的疾病或病症的有效治疗的剂量。治疗有效剂量可能因化合物与化合物以及患者与患者的不同而不同,并且可以取决于多种因素,诸如患者的病况和递送途径。治疗有效剂量可以根据本领域的技术人员已知的常规药理学程序来确定。
“媒剂”是指与化合物一起施用于患者的稀释剂、赋形剂或载体。媒剂可以是药学上可接受的媒剂。药学上可接受的媒剂是本领域已知的。
现在参考结晶5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐二水合物、制备该结晶盐的方法、包含该结晶盐的药物组合物和该结晶盐的用途。所公开的结晶盐、药物组合物、方法和用途不旨在限制权利要求。相反,权利要求旨在涵盖所有替代、修改和等同物。
化合物(1)(结晶5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐二水合物)是5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺(化合物(2))的稳定盐。化合物(1)具有以下结构:
5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺是一种底物选择性p38αMAPK抑制剂。5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺(游离碱,化合物2)具有式(2)的结构:
化合物(2)的合成方法和化合物(2)的性质公开于PCT国际公开号WO 2020/118194中。
化合物(1)(结晶5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐二水合物)是游离碱化合物(2)的稳定盐。
结晶5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐二水合物盐可以如实例1中所述制备。
化合物(1)可由XRPD图案表征,该XRPD图案包含至少在10.5°±0.2°、13.9°±0.2°、14.8°±0.2°、17.2±0.2°、20.4±0.2°、22.6±0.2°、25.7±0.2°和27.9±0.2°处的以2θ角表示并且使用Cu-Kα辐射确定的特征衍射峰。
化合物(1)可由XRPD图案表征,该XRPD图案包含至少在10.5°±0.1°、13.9°±0.1°、14.8°±0.1°、17.2±0.1°、20.4±0.1°、22.6±0.1°、25.7±0.1°和27.9±0.2°处的以2θ角表示并且使用Cu-Kα辐射确定的特征衍射峰。
化合物(1)可由XRPD图案表征,该XRPD图案包含至少在7.5±0.2°、8.5±0.2°、10.5°±0.2°、12.8±0.2°、13.9°±0.2°、14.8°±0.2°、15.5±0.2°、17.2±0.2°、18.2±0.2°、20.1±0.2°、20.4±0.2°、21.1±0.2°、22.6±0.2°、22.9±0.2°、23.5±0.2°、23.8±0.2°、24.6±0.2°、25.7±0.2°、26.1±0.2°、26.4±0.2°、27.1±0.2°、27.5±0.2°、27.9±0.2°和32.4±0.2°处的以2θ角表示并且使用Cu-Kα辐射确定的特征衍射峰。
化合物(1)可由XRPD图案表征,该XRPD图案包含至少在7.5±0.1°、8.5±0.1°、10.5°±0.1°、12.8±0.1°、13.9°±0.1°、14.8°±0.1°、15.5±0.1°、17.2±0.1°、18.2±0.1°、20.1±0.1°、20.4±0.1°、21.1±0.1°、22.6±0.1°、22.9±0.1°、23.5±0.1°、23.8±0.1°、24.6±0.1°、25.7±0.1°、26.1±0.1°、26.4±0.1°、27.1±0.1°、27.5±0.1°、27.9±0.1°和32.4±0.1°处的以2θ角表示并且使用Cu-Kα辐射确定的特征衍射峰。
化合物(1)可由基本上如图1所示的XRPD图案表征。
化合物(1)可具有例如161℃至167℃(诸如162℃至166℃或163℃至165℃)的熔融起始温度,其中熔融起始温度通过差示扫描量热法确定。
化合物(1)可具有例如164.3℃±0.5℃(诸如164.3℃±0.25℃或164.3℃±0.1℃)的熔融起始温度,其中熔融起始温度通过差示扫描量热法确定。
化合物(1)可具有例如89J/g至99J/g、91J/g至97J/g或93J/g至95J/g的熔融焓,其中熔融焓通过差示扫描量热法确定。
化合物(1)可具有例如94.25J/g±0.5J/g(诸如94.2J/g±0.25J/g或94.2J/g±0.1J/g)的熔融焓,其中熔融焓通过差示扫描量热法确定。
化合物(1)可具有例如178.5J/g至184.5J/g、179.5J/g至183.5J/g、或179.5J/g至182.5J/g的熔融峰,其中熔融峰通过差示扫描量热法确定。
化合物(1)可具有例如在181.6℃±2.0℃(诸如181.6℃±1.0℃或181.6℃±05℃)的熔融峰,其中熔融峰通过差示扫描量热法确定。
化合物(1)可以表现出基本上如图2所示的差示扫描量热曲线。
化合物(1)在25℃至210℃的温度下可具有例如13%至15%的重量损失,诸如在25℃至210℃的温度下可以具有13.3%至14.7%的重量损失,或在25℃至210℃的温度下可以具有13.6%至14.4%的重量损失,其中重量损失通过热重分析以2℃/min的扫描速率确定。
化合物(1)在25℃至210℃的温度下可具有例如13.9%±1.0%(诸如13.9%±0.5%或13.9%±0.2%)的重量损失,其中重量损失通过热重分析以2℃/min的扫描速率确定。
本公开提供的化合物(1)可以表现出基本上如图3所示的差热量热曲线。
化合物(1)在25℃至122℃的温度下可具有例如2%至6%的重量损失,诸如在25℃至122℃的温度下可以具有3%至5%的重量损失,或在25℃至122℃的温度下可以具有3.75%至4.75%的重量损失,其中重量损失通过热重分析以4.25℃/min的扫描速率确定。
化合物(1)在25℃至122℃的温度下可具有例如4.25%±1.0%(诸如4.25%±0.5%或4.25%±0.2%)的重量损失,其中重量损失通过热重分析以4.25℃/min的扫描速率确定。
本公开提供的化合物(1)可以表现出基本上如图4所示的差热量热曲线。
化合物(1)可具有例如5.8mol%至6.6mol%(诸如5.9mol%至6.5mol%、6.0mol%至6.4mol%、6.1mol%至6.3wt%或6.2mol%)的水含量,其中mol%是基于化合物(1)的总摩尔数。
5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺游离碱可以如PCT国际公开号WO 2020/118194中所述制备。
结晶的无水化合物(2)的XRPD图案示出于图5中。
化合物(2)可由XRPD图案表征,该XRPD图案包含至少在13.1°±0.2°、14.6°±0.2°、15.0°±0.2°、18.1±0.2°、22.2±0.2°、22.6±0.2°和24.4±0.2°处的以2θ角表示并且使用Cu-Kα辐射确定的特征衍射峰。
化合物(2)可由XRPD图案表征,该XRPD图案包含至少在13.1°±0.1°、14.6°±0.1°、15.0°±0.1°、18.1±0.1°、22.2±0.1°、22.6±0.1°和24.4±0.1°处的以2θ角表示并且使用Cu-Kα辐射确定的特征衍射峰。
化合物(2)可具有例如158℃至164℃(诸如159℃至163℃或160℃至162℃)的初次熔融起始温度,其中熔融起始温度通过差示扫描量热法确定。
化合物(2)可具有例如160.9℃±0.5℃(诸如160.9℃±0.25℃或160.9℃±0.1℃)的初次熔融起始温度,其中熔融起始温度通过差示扫描量热法确定。
化合物(2)可具有例如60J/g至65J/g、61J/g至65J/g或62J/g至4J/g的初次熔融焓,其中熔融焓通过差示扫描量热法确定。
化合物(2)可具有例如62.8J/g±0.5J/g(诸如62.8J/g±0.25J/g或62.8J/g±0.1J/g)的初次熔融焓,其中熔融焓通过差示扫描量热法确定。
化合物(2)可具有例如175J/g至182J/g、176J/g至181J/g或177J/g至180J/g的初次熔融峰,其中熔融峰通过差示扫描量热法确定。
化合物(2)可具有例如在177.8℃±2.0℃(诸如177.8℃±1.0℃或177.8℃±0.5℃)的初次熔融峰,其中熔融峰通过差示扫描量热法确定。
化合物(2)可具有204.7℃的二次熔融起始温度、20.7J/g的二次熔融焓和在211.2℃的二次熔融峰。
化合物(2)可以表现出基本上如图6所示的差示扫描量热曲线。
结晶5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐一水合物(化合物(3))可以通过将结晶5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐暴露于水分来得到。二盐酸盐一水合物可具有3.9mol%的水含量。
5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐一水合物的XRPD图案示出在图7中。
二盐酸盐一水合物可由XRPD图案表征,该XRPD图案包含至少在13.1°±0.2°、14.7°±0.2°、18.1°±0.2°、22.2±0.2°、22.6±0.2°、24.5±0.2°和25.7±0.2°处的以2θ角表示并且使用Cu-Kα辐射确定的特征衍射峰。
二盐酸盐一水合物可由XRPD图案表征,该XRPD图案包含至少在13.1°±0.1°、14.7°±0.1°、18.1°±0.1°、22.2±0.1°、22.6±0.1°、24.5±0.1°和25.7±0.1°处的以2θ角表示并且使用Cu-Kα辐射确定的特征衍射峰。
二盐酸盐一水合物可具有例如159℃至166℃(诸如160℃至165℃或161℃至164℃)的熔融起始温度,其中熔融起始温度通过差示扫描量热法确定。
二盐酸盐一水合物可具有例如162.9℃±0.5℃(诸如162.9℃±0.25℃或162.9℃±0.1℃)的熔融起始温度,其中熔融起始温度通过差示扫描量热法确定。
二盐酸盐一水合物在163℃至194℃的温度范围内可具有例如92J/g至98J/g、93J/g至97J/g或94J/g至96J/g的熔融焓,其中熔融焓通过差示扫描量热法确定。
二盐酸盐一水合物在163℃至194℃的温度范围内可具有例如94.9J/g±0.5J/g(诸如94.9J/g±0.25J/g或94.9J/g±0.1J/g)的熔融焓,其中熔融焓通过差示扫描量热法确定。
二盐酸盐一水合物可具有例如175J/g至182J/g、176J/g至181J/g或177J/g至180J/g的熔融峰,其中熔融峰通过差示扫描量热法确定。
二盐酸盐一水合物可具有例如在178.0℃±2.0℃(诸如178.0℃±1.0℃或178.0℃±0.5℃)的熔融峰,其中熔融峰通过差示扫描量热法确定。
二盐酸盐一水合物盐可以表现出基本上如图8所示的差示扫描量热曲线。
可以使用本领域已知的方法合成化合物(1)。
化合物(1)可以根据PCT国际公开号PCT/US2019/064960的第[00277]段中公开的方案5或如实例1中所述制备。
为制备二盐酸盐,5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺(游离碱)可在甲醇中与在有机溶剂中的氯化氢反应以提供5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐。为了提供二盐酸盐二水合物盐,可将二盐酸盐悬浮于甲醇(3.0vol)和水(2.0eq)中并在25℃至30℃搅拌1小时。可将固体过滤并用甲醇(1.5vol)洗涤以提供水含量为6.2mol%的化合物(1)
本公开提供的药物组合物可包含化合物(1)。
药物组合物可包含用于治疗患者的疾病的治疗有效量的化合物(1)。
药物组合物可包含一种或多种药学上可接受的载体、赋形剂稀释剂或任何前述的组合。
化合物(1)可以掺入药物组合物中以通过任何合适的施用途径向患者施用,包括皮内、肌内、腹膜内、静脉内、皮下、鼻内、硬膜外、口服、经口、舌下、脑内、阴道内、透皮、直肠、吸入或局部。本公开提供的药物组合物可以是可注射制剂。本公开提供的药物组合物可以是可注射静脉内制剂。本公开提供的药物组合物可以是口服制剂。口服制剂可以是口服剂型。可以配制药物组合物用于静脉内施用或皮下施用。
本公开提供的药物组合物可以包含治疗有效量的化合物(1)以及合适量的一种或多种药学上可接受的媒剂,以便提供用于向患者适当施用的组合物。合适的药物媒剂和制备药物组合物的方法在本领域中有所描述。
在向患者施用后,化合物(1)将解离以提供母体化合物,即5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐(化合物(2))。
本公开提供的药物组合物可以配制用于口服施用。配制用于口服施用的药物组合物可包含任何合适的口服剂型,包括例如片剂、胶囊、囊片、小袋、瓶、棒状包装、分散体和悬浮液。
配制用于口服施用的药物组合物可以在胃肠道中提供调释概况,诸如控制释放概况、持续释放概况、pH释放概况、脉冲释放概况、定时释放概况或延迟释放概况。配制用于口服施用的药物组合物可以被配置成在摄取后的预定时间段内和/或在胃肠道的预定区域中释放化合物(1)。
配制用于口服施用的药物组合物可以提供常释概况。
评估单个患者对治疗的应答并使患者有资格获得最佳治疗是现代医疗保健面临的最大挑战之一,并且与个体化用药的趋势相关。化合物(1)可具有靶向选择性,例如,对于某些癌症和免疫细胞具有靶向选择性。将化合物(1)放射性标记以用于正电子发射断层扫描(PET)或单光子发射计算机断层扫描(SPECT)可用于基于单一研究、个案患者分析预测治疗的靶向性,从而排除预计不会从治疗中获益的患者。使用化合物(1)的PET/SPECT扫描一旦与浓度相关联就可以提供三维分布图,然后可以将其用于宏观剂量计算。
因此,本领域技术人员有能力测定和使用化合物(1)和/或其药物组合物进行治疗。
化合物(1)和/或其药物组合物通常可以有效实现预期目的的量使用。为了用于治疗疾病(诸如癌症、自身免疫性疾病或炎性疾病),化合物(1)可以治疗有效量施用或应用。
有效治疗本文公开的特定病症或病况的化合物(1)的量将部分取决于病症或病况的性质,并且可以通过本领域已知的标准临床技术来确定。此外,可以任选地采用体外或体内测定来帮助确定最佳剂量范围。除其他因素外,化合物(1)的量可取决于正在治疗的患者、患者的体重、病痛的严重程度、施用方式和处方医师的判断。
在用于人类之前,可以在体外和体内测定化合物(1)的所需治疗活性。例如,体外测定可用于确定具体化合物或化合物组合的施用是否是优选的。使用动物模型系统也可以证明该化合物是有效和安全的。
治疗有效剂量的化合物(1)和/或其药物组合物将提供治疗益处而不引起显著毒性。化合物(1)和/或其药物组合物的毒性可以使用标准药物程序确定并且可以容易地由技术人员确定。毒性作用与治疗作用之间的剂量比为治疗指数。化合物(1)和/或其药物组合物在治疗疾病和病症方面表现出特别高的治疗指数。化合物(1)和/或其药物组合物的剂量可以在包括毒性最小的有效剂量的循环浓度范围内。
化合物(1)或其药物组合物可包括在试剂盒中,该试剂盒可用于将化合物施用于患者以用于治疗目的。试剂盒可包括包含适合于向患者施用的化合物(1)的药物组合物以及用于将药物组合物施用于患者的说明。试剂盒可适用于治疗癌症、适用于治疗自身免疫性疾病或适用于治疗炎性疾病。试剂盒可包含化合物(1)、用于施用共晶的药学上可接受的媒剂和用于将包含共晶的制剂施用于患者的说明。
药物组合物可以与施用说明书一起包括在容器、包装或分配器中。
与试剂盒一起提供的说明可以作为例如电子可读介质、录像带、录音带、闪存设备打印和/或供应,或者可以在因特网网址上发布或作为电子信息分发给患者和/或医疗保健提供者。
化合物(1)和包含化合物(1)的药物组合物可用于治疗其中疾病的病因与p38αMAPK蛋白活性相关的疾病。
化合物(1)在体内解离以提供化合物(2),其为p38αMAPK的选择性抑制剂。选择性p38αMAPK抑制剂对p38αMAPK靶标口袋的结合亲和力高于对p38αMAPK催化结合位点的结合亲和力。p38αMAPK抑制剂可以在p38αMAPK的底物结合沟附近与p38αMAPK结合,该底物结合沟在两个酸性区域(CD和ED结构域)之间延伸。结合口袋可至少由p38αMAPK的残基R49、H107、L108和K165定义。结合口袋可至少由p38αMAPK的残基R49、H107、L108、M109、G110、A157、V158、E163、L164和K165定义。
可以使用互补技术确认化合物(2)p38αMAPK的选择性结合。例如,选择性p38αMAPK抑制剂可以显示出p38α而非p38P的解链温度的浓度依赖性增加,如使用DSF所确定的,DSF检测配体诱导的蛋白质稳定性。通过从蛋白质到配体质子的非标量磁化转移来测量低亲和力蛋白质/配体结合的STD-NMR可用于证实化合物与p38α的特异性结合,并将相互作用定位于其芳环。p38αMAPK抑制剂可引起p38αMAPK解链温度的浓度依赖性增加。可以在1nM与1000μM之间的p38αMAPK抑制剂浓度(诸如100μM的浓度)下测量解链温度Tm的差异。例如,解链温度的差异可以为0.1℃和约2℃。
化合物(2)可以与p38 MAPK的ED底物对接位点附近的口袋相互作用。
化合物(2)可以在p38αMAPK的底物结合沟附近与p38αMAPK结合,它在CD和ED结构域之间延伸。
化合物(2)可通过与p38αMAPK的相互作用抑制MK2磷酸化。
化合物(2)可以与4-氯-N-(4-((1,1-二氧硫代吗啉基)甲基)苯基)苯甲酰胺竞争性结合p38αMAPK。
化合物(2)对p38αMAPK亚基的结合亲和力高于对p38βMAPK亚基的结合亲和力。
p38αMAPK抑制剂可具有例如-5至10、-3至8、0至5、0.1至3、0.1至1、0.5至1.5、0.75至2、1至2.5或1.75至3的logP。LogP是药物溶解度的量度,并且被定义为药物的辛醇/水分配系数的对数。
MK2的磷酸化需要与p38αMAPK中与靶标口袋相邻的ED位点结合。靶标口袋可由p38αMAPK中的氨基酸R49、H107、L108和K165定义。靶标口袋可由p38αMAPK中选自R49、H107、L108、M109、G110、A157、V158、E163、L164和K165的氨基酸定义。靶标口袋可由p38αMAPK中的氨基酸R49、H107、L108、M109、G110、A157、V158、E163、L164和K165定义。
化合物(2)可以至少部分地抑制MK2磷酸化。例如,Western印迹可用于测量茴香霉素刺激的HeLa细胞中化合物(2)对MK2磷酸化的抑制。
化合物(2)可以稳定内皮或上皮屏障功能。内皮屏障渗透性可以通过单独或组合暴露于TNFa和高热,然后测量对10kDa葡聚糖的渗透性来测量。例如,通过在渗透性测量之前和之后用化合物(2)预处理来评估内皮屏障稳定性,其中稳定化可表示为预处理之前和之后渗透性增加的降低百分比。10kDa葡聚糖的渗透性增加可降低5%至超过100%,诸如例如大于5%、大于10%、大于20%、大于40%、大于60%、大于80%或大于100%。
化合物(2)可以调节人肺微血管内皮细胞(HMVECL)中TNFa诱导的基因表达,如使用例如RNASeq所确定的。例如,HMVECL可以用适当浓度的p38αMAPK抑制剂预处理一段时间,然后用TNFa刺激一段时间。化合物(1)可抑制基因,诸如PRRG4、TSLP、CCLI 7、EXOC3L4、MMP9、IDOI、CXCLlO、CD200、SLCI5A3、VDR、ILIB、GPR88、CD207、TCHH、HAS3、GBPIPI、MUC4、ELOVL7、CXCLll、GBP4、PLAIA和/或CXCL5。
p38αMAPK抑制剂对炎性细胞因子表达的影响可以通过用p38αMAPK抑制剂预处理PMA分化的THPI细胞,然后用LPS刺激,并在一段时间后收集RNA以用于通过基于PCR的细胞因子阵列进行分析来确定。p38αMAPK抑制剂可以抑制多种基因的表达,诸如IL-IA、IL-8、TNFSF8、CXCL5、CCL7、CCLI7、TNFSF9、IL-IB、CXCLI、TNFSFI5、CCL5、CCL4、CCL20、CXCL2、TNF或BMP6。p38αMAPK抑制剂可以抑制Smad3的表达,这驱动Foxp3 T调节细胞的分化并抑制干扰素-γ。可以通过比较在不同浓度的p38αMAPK抑制剂下mRNA的倍数变化水平与未刺激的PMA分化的THPI细胞来测量炎症降低。
化合物(1)或其药物组合物可用于治疗患者的疾病。
化合物(1)或其药物组合物可用于治疗其中疾病病因与p38αMAPK蛋白的上调和/或下调相关的疾病。
本公开提供的方法包括治疗患者的疾病,该方法包括向需要此类治疗的患者施用治疗有效量的化合物(1)或其药物组合物,其中通过抑制p38αMAPK蛋白来治疗该疾病。
应激和细胞因子活化的激酶的p38丝裂原活化蛋白激酶(MAPK)家族与许多人类疾病的发病机制有关,包括例如癌症、类风湿性关节炎、心血管疾病、多发性硬化症、炎性肠病、慢性阻塞性肺病(COPD)、哮喘、急性呼吸窘迫综合征(ARDS)和急性肺损伤(ALI)。在p38MAPK调节的许多重要生物学过程中,内皮和上皮屏障功能的调节、白细胞运输和细胞因子表达是急性和慢性炎性病症发病机制的核心。
化合物(1)或其药物组合物可用于治疗患者的癌症。癌症可以是例如实体瘤或转移瘤。
本公开提供的方法包括治疗患者的癌症的方法,该方法包括向需要此类治疗的患者施用治疗有效量的本公开提供的化合物或药物组合物。
合适的癌症的实例包括听神经瘤、腺癌、血管肉瘤、星形细胞瘤、基底细胞癌、胆管癌、膀胱癌、脑癌、乳腺癌、支气管癌、宫颈癌、脊索瘤、绒毛膜癌、结肠癌、结肠直肠癌、颅咽管瘤、囊腺癌、胚胎癌、内皮细胞癌、室管膜瘤、上皮癌、食道癌、尤因氏瘤、纤维肉瘤、胃癌、多形胶质母细胞瘤、神经胶质瘤、头颈癌、血管母细胞瘤、肝细胞瘤、肾癌、平滑肌肉瘤、脂肪肉瘤、肺癌、淋巴管内皮肉瘤、淋巴管肉瘤、髓样癌、髓母细胞瘤、黑色素瘤、脑膜瘤、间皮瘤、粘液肉瘤、鼻癌、神经母细胞瘤、少突胶质细胞瘤、口腔癌、骨原性肉瘤、卵巢癌、胰腺癌、乳头状腺癌、乳头状癌、松果体瘤、前列腺癌、横纹肌肉瘤、直肠癌、肾细胞癌、视网膜母细胞瘤、肉瘤、皮脂腺癌、精原细胞瘤、皮肤癌、鳞状细胞癌、胃癌、汗腺癌、滑膜瘤、睾丸癌、小细胞肺癌、喉癌、子宫癌、维尔姆斯瘤、血癌、急性红白血病、急性淋巴细胞性B细胞白血病、急性淋巴细胞性T细胞白血病、急性淋巴细胞性白血病、急性巨核细胞白血病、急性单核细胞白血病、急性髓细胞白血病、急性髓单核细胞白血病、急性非淋巴细胞性白血病、急性早幼粒细胞性白血病、急性未分化白血病、慢性淋巴细胞性白血病、慢性髓细胞白血病、毛细胞白血病、多发性骨髓瘤、重链疾病、霍奇金病、
合适的癌症的实例包括胰腺癌、乳腺癌、前列腺癌、淋巴瘤、皮肤癌、结肠癌、黑色素瘤、恶性黑色素瘤、卵巢癌、脑癌、原发性脑癌、头颈癌、神经胶质瘤、胶质母细胞瘤、肝癌、膀胱癌、非小细胞肺癌、头或颈癌、乳腺癌、卵巢癌、肺癌、小细胞肺癌、维尔姆斯瘤、宫颈癌、睾丸癌、膀胱癌、胰腺癌、胃癌、结肠癌、前列腺癌、泌尿生殖系统癌、甲状腺癌、食道癌、骨髓瘤、多发性骨髓瘤、肾上腺癌、肾细胞癌、子宫内膜癌、肾上腺皮质癌、恶性胰腺胰岛素瘤、恶性类癌、绒毛膜癌、蕈样真菌病、恶性高钙血症、宫颈增生、白血病、急性淋巴细胞性白血病、慢性淋巴细胞性白血病、急性骨髓性白血病、慢性骨髓性白血病、慢性粒细胞性白血病、急性粒细胞性白血病、毛细胞白血病、神经母细胞瘤、横纹肌肉瘤、卡波西氏肉瘤、真性红细胞增多症、原发性血小板增多症、霍奇金病、非霍奇金淋巴瘤、软组织肉瘤、骨原性肉瘤、原发性巨球蛋白血症或视网膜母细胞瘤等。在其他实施例中,癌症是听神经瘤、腺癌、血管肉瘤、星形细胞瘤、基底细胞癌、胆管癌、膀胱癌、脑癌、乳腺癌、支气管癌、宫颈癌、脊索瘤、绒毛膜癌、结肠癌、结肠直肠癌、颅咽管瘤、囊腺癌、胚胎癌、内皮细胞癌、室管膜瘤、上皮癌、食道癌、尤因氏瘤、纤维肉瘤、胃癌、多形胶质母细胞瘤、神经胶质瘤、头颈癌、血管母细胞瘤、肝细胞瘤、肾癌、平滑肌肉瘤、脂肪肉瘤、肺癌、淋巴管内皮肉瘤、淋巴管肉瘤、髓样癌、髓母细胞瘤、黑色素瘤、脑膜瘤、间皮瘤、粘液肉瘤、鼻癌、神经母细胞瘤、少突胶质细胞瘤、口腔癌、骨原性肉瘤、卵巢癌、胰腺癌、乳头状腺癌、乳头状癌、松果体瘤、前列腺癌、横纹肌肉瘤、直肠癌、肾细胞癌、视网膜母细胞瘤、肉瘤、皮脂腺癌、精原细胞瘤、皮肤癌、鳞状细胞癌、胃癌、汗腺癌、滑膜瘤、睾丸癌、小细胞肺癌、喉癌、子宫癌、维尔姆斯瘤、血癌、急性红白血病、急性淋巴细胞性B细胞白血病、急性淋巴细胞性T细胞白血病、急性淋巴细胞性白血病、急性巨核细胞白血病、急性单核细胞白血病、急性髓细胞白血病、急性髓单核细胞白血病、急性非淋巴细胞性白血病、急性早幼粒细胞性白血病、急性未分化白血病、慢性淋巴细胞性白血病、慢性髓细胞白血病、毛细胞白血病、多发性骨髓瘤、重链疾病、霍奇金病、多发性骨髓瘤、非霍奇金淋巴瘤、真性红细胞增多症或华氏巨球蛋白血症。
化合物(1)或其药物组合物可用于治疗例如以下癌症中的一种或多种:急性成淋巴细胞白血病、急性髓性白血病、肾上腺皮质癌、阑尾癌、星形细胞瘤、非典型畸胎样/横纹肌样肿瘤、基底细胞癌(非黑色素瘤)、B细胞淋巴瘤、膀胱癌、骨癌、脑和脊髓肿瘤、脑干癌、脑肿瘤、乳腺癌、支气管肿瘤、伯基特淋巴瘤、类癌瘤、头颈癌、中枢神经系统胚胎性肿瘤、小脑星形细胞瘤、脑星形细胞瘤/恶性胶质瘤、宫颈癌、脊索瘤、慢性淋巴细胞白血病、慢性骨髓性白血病、结肠直肠癌、颅咽管瘤、皮肤T细胞淋巴瘤、促结缔组织增生小圆细胞瘤、导管癌、染料癌、内分泌胰腺肿瘤(胰岛细胞瘤)、子宫内膜癌、室管膜瘤、食管癌、嗅神经母细胞瘤、尤因家族肿瘤、颅外生殖细胞瘤、肝外胆管癌、胆囊癌、胃癌、胃肠类癌瘤、胃肠间质瘤、妊娠滋养层肿瘤、胶质母细胞瘤、胶质瘤、毛细胞白血病、头颈癌、心脏癌、淋巴谱系造血肿瘤、肝细胞癌、霍奇金淋巴瘤、下咽癌、下丘脑和视觉通路胶质瘤、ID相关淋巴瘤、眼内黑色素瘤、胰岛细胞瘤、卡波西肉瘤、肾癌、朗格汉斯细胞组织细胞增生症、喉癌、白血病、唇和口腔癌、男性乳腺癌、恶性纤维组织细胞瘤、恶性生殖细胞瘤、恶性间皮瘤、髓母细胞瘤、黑色素瘤、默克尔细胞癌、间皮瘤、口腔癌、多发性内分泌肿瘤综合征、多发性骨髓瘤、蕈样真菌病、脊髓发育不良、骨髓增生性肿瘤、鼻腔和副鼻窦癌、鼻咽癌、神经母细胞瘤、非霍奇金淋巴瘤、非小细胞肺癌、口腔癌、口咽癌、骨肉瘤、卵巢癌、卵巢上皮癌、卵巢生殖细胞瘤、卵巢低恶性潜能肿瘤、胰腺癌、胰腺神经内分泌肿瘤(胰岛细胞瘤)、乳头状瘤病、副神经节瘤、副鼻窦和鼻腔癌、甲状旁腺癌、阴茎癌、咽癌、嗜铬细胞瘤、松果体实质肿瘤、松果体母细胞瘤和幕上原始神经外胚层肿瘤、垂体肿瘤、浆细胞瘤/多发性骨髓瘤、胸膜肺母细胞瘤、妊娠期乳腺癌、原发性中枢神经系统淋巴瘤、原发性肝癌、隐匿性原发性转移性鳞状颈癌、前列腺癌、直肠癌、肾细胞癌、肾盂和输尿管、呼吸道癌、视网膜母细胞瘤、横纹肌肉瘤、唾液腺癌、肉瘤、塞扎里综合征、皮肤癌、小肠癌、软组织肉瘤、鳞状细胞癌(非黑色素瘤)、胃癌、幕上原始神经外胚层肿瘤、T细胞淋巴瘤、睾丸癌、喉癌、胸腺瘤和胸腺癌、甲状腺癌、移行细胞癌、尿道癌、子宫肉瘤、阴道癌、视通路和下丘脑神经胶质瘤、外阴癌、华氏巨球蛋白血症、威尔姆氏瘤、以及任何前述的全身性和中枢转移瘤。
本公开提供的方法包括治疗癌症的方法,其中癌症选自乳腺癌和黑色素瘤。
本公开提供的方法包括治疗患者的炎性疾病的方法,该方法包括向需要此类治疗的患者施用治疗有效量的本公开提供的化合物或药物组合物。
炎性疾病的实例包括过敏、阿尔茨海默病、贫血、强直性脊柱炎、关节炎、动脉粥样硬化、哮喘、孤独症、关节炎、腕管综合征、乳糜泻、结肠炎、克罗恩病、充血性心力衰竭、皮炎、糖尿病、憩室炎、湿疹、纤维肌痛、纤维化、胆囊疾病胃食管反流病、桥本氏甲状腺炎、心脏病发作、肝炎、肠易激综合征、肾衰竭、狼疮、多发性硬化症、肾炎、神经病、胰腺炎、帕金森氏病、银屑病、风湿性多肌痛、类风湿性关节炎、硬皮病、中风、手术并发症和溃疡性结肠炎。
本公开提供的方法包括治疗患者的炎性疾病的方法,其中炎性疾病选自例如急性呼吸窘迫综合征、局灶性节段性肾小球肾炎、动脉粥样硬化/急性冠脉综合征、慢性阻塞性肺病、哮喘、炎性肠病、克罗恩病、银屑病、狼疮、多发性硬化症、高胆固醇血症的炎症、疼痛、糖尿病和类风湿性关节炎。
本公开提供的方法包括治疗患者的自身免疫性疾病的方法,该方法包括向需要此类治疗的患者施用治疗有效量的本公开提供的化合物或药物组合物。
化合物(1)或其药物组合物可用于治疗自身免疫性疾病。自身免疫性疾病可以定义为免疫系统攻击其自身的蛋白质、细胞和/或组织的人类疾病。可以在例如TheAutoimmune Diseases,Rose and Mackay,2014,Academic Press中找到自身免疫性疾病的综合列表和综述。
自身免疫性疾病的实例包括爱迪生氏病、无丙种球蛋白血症、斑秃、淀粉样变性、强直性脊柱炎、抗GBM/抗TBN肾炎、抗磷脂综合征、自身免疫性血管性水肿、自身免疫性自主异常、自身免疫性脑脊髓炎、自身免疫性肝炎、自身免疫性内耳疾病、自身免疫性心肌炎、自身免疫性胰腺炎、自身免疫性视网膜病、自身免疫性荨麻疹、轴突和神经元神经病、Balo病、白塞氏病、良性粘膜类天疱疮、大疱性类天疱疮、卡斯尔曼病、乳糜泻、查加斯病、慢性炎症性脱髓鞘性多发性神经病、慢性复发性多病灶性骨髓炎、查格-施特劳斯病、瘢痕性类天疱疮、Cogan综合征、冷凝集素病、先天性心脏病、柯萨奇心肌炎、CREST综合征、克罗恩病、疱疹样皮炎、皮肌炎、Devic氏病、盘状狼疮、德雷斯勒综合征、子宫内膜异位症、嗜酸性食管炎、嗜酸性筋膜炎、结节性红斑、原发性混合冷球蛋白血症、埃文斯综合征、纤维肌痛、纤维化肺泡炎、巨细胞动脉炎、巨细胞心肌炎、肾小球肾炎、古德佩斯特氏综合征、肉芽肿性多血管炎、格雷夫斯病、格林-巴利综合征、桥本甲状腺炎、溶血性贫血、Henoch-Schonlein紫癜、妊娠疱疹或妊娠性类天疱疮、低丙种球蛋白血症、IgA肾病、IgG4相关硬化性病、免疫性血小板减少性紫癜、包涵体肌炎、间质性膀胱炎、幼年型关节炎、幼年型糖尿病、幼年型肌炎、川崎氏病、Lambert-Eaton综合征、白血球破碎性血管炎、扁平苔藓、硬化性苔藓、木样结膜炎、线性IgA疾病、狼疮、慢性莱姆病、梅尼埃病、显微镜下多血管炎、混合结缔组织病、莫伦角膜溃疡、Mucha-Habermann病、多发性硬化症、重症肌无力、肌炎、发作性睡病、视神经神经脊髓炎、中性粒细胞减少症、眼部瘢痕性天疱疮、视神经炎、复发性风湿病、PANDAS、副肿瘤性小脑变性、阵发性夜间血红蛋白尿、帕罗综合征、睫状体扁平部炎、帕森纳-特纳综合征、天疱疮、周围神经病、静脉周脑脊髓炎、恶性贫血、POEMS综合征、结节性多动脉炎、多腺性综合征、风湿性多肌痛、多肌炎、心肌梗死后综合征、心包切开术后综合征、原发性胆汁性肝硬化、原发性硬化性胆管炎、孕酮性皮炎、银屑病、银屑病性关节炎、纯红细胞再生障碍、坏疽性脓皮病、雷诺现象、反应性关节炎、反射性交感神经营养不良、复发性多软骨炎、不宁腿综合征、腹膜后纤维化、风湿热、类风湿性关节炎、结节病、施密特综合征、巩膜炎、硬皮病、干燥综合征、精子和睾丸自身免疫、僵人综合征、亚急性细菌性心内膜炎、Susac综合征、交感性眼炎、大动脉炎、颞动脉炎、血小板减少性紫癜、Tolosa-Hunt综合征、横贯性脊髓炎、1型糖尿病、溃疡性结肠炎、未分化结缔组织病、葡萄膜炎、血管炎、白癜风和韦格纳肉芽肿。
化合物(1)或其药物组合物可用于治疗自身免疫性病症,诸如例如狼疮、移植物抗宿主病、丙型肝炎诱发的血管炎、I型糖尿病、多发性硬化症、自发流产、特应性疾病和炎性肠病。
化合物(1)或其药物组合物可以与一种或多种用于治疗自身免疫性疾病的另外的治疗剂一起施用。化合物(1)或其药物组合物可与一种或多种免疫抑制剂联合施用,包括例如皮质类固醇,诸如泼尼松、布地奈德和泼尼松龙;Janus激酶抑制剂,诸如托法替尼;钙调神经磷酸酶抑制剂,诸如环孢菌素和他克莫司;mTOR抑制剂,诸如西罗莫司和依维莫司;IMDH抑制剂,诸如硫唑嘌呤、来氟米特和霉酚酸酯;生物制剂,诸如阿巴西普阿达木单抗、阿那白滞素、赛妥珠单抗、依那西普、戈利木单抗、英夫利西单抗、ixekizumab、那他珠单抗、利妥昔单抗、苏金单抗、托珠单抗、乌司奴单抗和维多珠单抗;和单克隆抗体,诸如巴利昔单抗和达利珠单抗。
本公开提供的方法包括治疗患者的疾病的方法,该方法包括向需要此类治疗的患者施用治疗有效量的化合物(1),其中该疾病选自急性冠脉综合征、急性肺损伤、急性呼吸窘迫综合征(ARDS)、阿尔茨海默病、哮喘、心血管疾病、慢性阻塞性肺病(COPD)、炎性肠病、重度抑郁症、多发性硬化症、神经性疼痛和类风湿性关节炎。可以将化合物(1)或其药物组合物施用于患者以治疗病毒感染(诸如COVID19感染)的症状。
本公开提供的方法包括治疗患者的疾病的方法,该方法包括向需要此类治疗的患者施用治疗有效量的化合物(1),其中该疾病是呼吸系统疾病。
本公开提供的方法包括治疗患者的疾病的方法,该方法包括向需要此类治疗的患者施用治疗有效量的本公开提供的化合物或药物组合物,其中该疾病是年龄相关性疾病,诸如例如听力损失、肌肉退化、沃纳综合征、细胞老化或阿尔茨海默病。
本公开提供的方法包括治疗患者的疾病的方法,该方法包括向需要此类治疗的患者施用此类治疗的治疗有效量的化合物(1)或药物组合物,其中该疾病选自突发性特发性听力损失、药物性听力损失、年龄相关性听力损失和杜氏肌营养不良症。
在治疗癌症中有效的化合物(1)或其药物组合物的量可以至少部分地取决于疾病的性质,并且可以通过本领域已知的标准临床技术来确定。此外,可以采用体外或体内测定来帮助确定最佳剂量范围。给药方案和给药间隔也可以通过本领域技术人员已知的方法来确定。除其他因素外,所施用的化合物(1)的量可取决于正在治疗的患者、患者的体重、疾病的严重程度、施用途径和处方医师的判断。
对于全身性施用,治疗有效剂量可以最初从体外测定中估计。还可以使用本领域已知的技术从体内数据例如动物模型估计初始剂量。此类信息可用于更准确地确定人体的有用剂量。本领域普通技术人员可以基于动物数据优化对人的施用。
可以选择化合物(1)的剂量和合适的给药间隔以维持化合物(2)在患者血液中的持续治疗有效浓度,并且在某些实施例中不超过最小不利浓度。
包含化合物(1)的药物组合物可以例如每天4次、每天两次、每天一次、每周一次、每2周一次、每3周一次、每4周一次、每5周一次或每6周一次施用。给药可以单独提供或与其他药物组合提供并且可以持续至有效治疗疾病所需的时间。也可以在一段时间内使用连续或半连续施用来进行给药。给药包括将药物组合物施用于进食或禁食状态下的哺乳动物,诸如人。
药物组合物可以单剂型或多剂型或作为连续或累积剂量在一段时间内施用。当使用多剂型时,多剂型中每一种内所含的化合物(1)的量可以相同或不同。
合适的每日施用剂量范围可以是例如每千克体重约2μg至约200mg化合物(1)。
合适的每日施用剂量范围可以是例如每平方米(m2)体表约1μg至约50mg化合物(1)。
化合物(1)可以以例如0.001mg/天至100mg/天的量或以任何其他合适的日剂量施用以治疗患者的癌症。剂量可以是例如0.01μg/kg体重/周至100μg/kg体重/周或任何其他合适的剂量。
可以施用包含化合物(1)的药物组合物来治疗患者的癌症,以便在患者的血液或血浆中提供治疗有效浓度的化合物(2)。化合物(1)的化合物在患者血液中的治疗有效浓度可以是例如0.01μg/L至1,000μg/L、0.1μg/L至500μg/L、1μg/L至250μg/L,或约10μg/L至约100μg/L。化合物(2)在患者血液中的治疗有效浓度可以是例如至少0.01μg/L、至少0.1μg/L、至少1μg/L、至少约10μg/L或至少100μg/L。化合物(2)在患者血液中的治疗有效浓度可以例如小于引起不可接受的不良反应(包括对体内平衡的不良反应)的量。化合物(2)在患者血液中的治疗有效浓度可以是足以恢复和/或维持患者的体内平衡的量。
可以施用本公开提供的药物组合物来治疗患者的疾病以便在患者血液中提供治疗有效浓度的化合物(2)持续一段时间,诸如例如4小时、8小时、12小时、16小时、20小时、1天或2天。
化合物(1)的施用量可以在治疗方案期间变化。
除化合物(1)外,本公开提供的药物组合物可进一步包括一种或多种药物活性化合物。可以提供此类化合物,例如以治疗用化合物(2)治疗的癌症或以治疗除了用化合物(2)正接受治疗的癌症之外的疾病、病症或病况,以治疗由化合物(2)引起的副作用,以增强化合物(2)的功效和/或以调节化合物(2)的活性。
化合物(1)可以与至少一种其他治疗剂组合施用。化合物(1)可以与另一种化合物一起施用于患者以治疗患者的癌症。化合物(1)和至少一种其他治疗剂可以累加地或在某些实施例中协同地起作用。至少一种另外的治疗剂可以包括在包含化合物(1)的同一药物组合物或媒剂中,或可以在单独的药物组合物或媒剂中。因此,本公开提供的方法进一步包括除了施用化合物(1)之外,施用一种或多种用于有效治疗癌症或不同于癌症的疾病、病症或病况的治疗剂。本公开提供的方法包括施用化合物(1)和一种或多种其它治疗剂,条件是组合施用不抑制化合物(2)的治疗功效和/或不产生不利的组合效应。
包含化合物(1)的药物组合物可以与另一种治疗剂的施用同时施用,该另一种治疗剂可以是与包含化合物(1)的相同的药物组合物的一部分,或者是与包含该化合物的不同的药物组合物的一部分。化合物(1)可以在施用另一种治疗剂之前或之后施用。在某些组合疗法中,组合疗法可包括交替施用化合物(1)和包含另一种治疗剂的组合物,例如以将与特定药物相关的不良药物作用最小化。当化合物(1)与潜在地可以产生不良药物作用(包括例如毒性)的另一种治疗剂同时施用时,其他治疗剂可以以落在引发不良药物反应的阈值以下的剂量施用。
包含化合物(1)的药物组合物可以与一种或多种物质一起施用,例如,以增强、调节和/或控制化合物(1)和/或化合物(2)的释放、生物利用度、治疗功效、治疗效力和/或稳定性。例如,包含化合物(1)的药物组合物可以与具有增强化合物(2)的治疗功效的药理作用的活性剂共同施用。
化合物(1)或其药物组合物可以与已知或被认为有效治疗患者的疾病(诸如癌症、自身免疫性疾病或炎性疾病,诸如与用化合物(1)正在治疗的疾病相同)的药剂联合施用。
化合物(1)或其药物组合物可以与已知或被认为干扰细胞增殖的药剂联合施用。
化合物(1)或其药物组合物可以与已知或被认为干扰细胞代谢,作为抗代谢物,干扰RNA转录,干扰RNA翻译,干扰细胞蛋白质合成,干扰DNA合成和复制的前体的合成,干扰嘌呤合成,干扰核苷合成,与mTOR相互作用,作为mTOR抑制剂,干扰细胞周期检查点的药剂联合施用。
化合物(1)或其药物组合物可以与检查点抑制剂联合施用,该检查点抑制剂包括CTLA-4抑制剂,诸如易普利姆玛;PD-1抑制剂,诸如帕博利珠单抗和纳武单抗;和/或PD-L1抑制剂,诸如阿特珠单抗、阿维鲁单抗和德瓦鲁单抗。化合物(1)或其药物组合物可以与免疫调节剂(诸如CD137/4-1BB、CD27、GIYR和/或OC40)联合施用。
化合物(1)或其药物组合物可以与已知或被认为具有细胞毒性的药剂联合施用,以引起DNA损伤,引起细胞周期停滞或引起有丝分裂灾难。
化合物(1)或其药物组合物可以与已知或被认为调节谷胱甘肽浓度,调节细胞内谷胱甘肽浓度,降低细胞内谷胱甘肽浓度,减少细胞内谷胱甘肽摄取,减少谷胱甘肽合成或减少细胞内谷胱甘肽合成的药剂联合施用。
化合物(1)或其药物组合物可以与已知或被认为干扰新血管形成、减少新血管形成或促进新血管形成的药剂联合施用。
化合物(1)或其药物组合物可以与已知或被认为干扰激素体内平衡,干扰激素合成,干扰激素受体结合或干扰激素信号转导的药剂联合施用。
化合物(1)或其药物组合物可以与已知或被认为干扰生长因子体内平衡,干扰生长因子受体表达,干扰生长因子与生长因子受体结合,干扰生长因子受体信号转导,干扰Hedgehog(Hh)信号传导,抑制Hedgehog通路信号传导,抑制ALK(间变性淋巴瘤激酶)通路信号传导或抑制非同源末端连接(NHEJ)通路的药剂联合施用。
化合物(1)或其药物组合物可以与一种或多种已知或被认为是以下物质的药剂联合施用:VEGFR(血管内皮生长因子受体)抑制剂、RTK(受体酪氨酸激酶)抑制剂、钠通道电流阻断剂、aFAK(黏着斑激酶)抑制剂、GLI(胶质瘤相关致癌基因)抑制剂、GLI1抑制剂、GLI2抑制剂、GLI3抑制剂、MAPK(丝裂原活化蛋白激酶)抑制剂、MAPK/ERK途径(也称为Ras-Raf-MEK-ERK途径)抑制剂、MEK1抑制剂、MEK2抑制剂、MEK5抑制剂、MEK5/ERK5抑制剂、aRTA(肾小管酸中毒)抑制剂、ALK(间变性淋巴瘤激酶)抑制剂、Aa LK激酶抑制剂、核易位抑制剂、PORCN(豪猪)抑制剂、5-ARI(5α-还原酶抑制剂)、拓扑异构酶抑制剂、Ras(大鼠肉瘤)抑制剂、K-ras抑制剂、CERK(神经酰胺激酶)抑制剂、PKB(蛋白激酶B,也称为AKT)抑制剂、AKT1抑制剂、EZH2(Zeste基因增强子同源物2)抑制剂、BET(溴结构域和超末端结构域基序)抑制剂、SYK(脾酪氨酸激酶)抑制剂、JAK(janus激酶)抑制剂、SYK/JAK抑制剂、IDO(吲哚胺-吡咯-2,3-双加氧酶)抑制剂、IDO1抑制剂、RXR(维甲酸X受体)活化剂、选择性RXR活化剂、p-糖蛋白抑制剂、ERK抑制剂、PI3K(磷脂酰肌醇-4,5-二磷酸3-激酶)抑制剂、BRD(含溴结构域蛋白)抑制剂、BRD2抑制剂、BRD3抑制剂、BRD4抑制剂、BRDT(溴结构域睾丸特异性蛋白)、逆转录酶抑制剂、NRT(核苷类似物逆转录酶)抑制剂、PIM(莫洛尼病毒前病毒整合)抑制剂、EGFR(表皮生长因子受体)抑制剂、光敏剂、放射增敏剂、ROS(原癌基因、受体酪氨酸激酶)抑制剂、ROS1(原癌基因1)抑制剂、CK(酪蛋白激酶)抑制剂、CK2抑制剂、Bcr-Abl(断裂点丛集区-阿贝尔森原癌基因)酪氨酸激酶抑制剂诸如达沙替尼、微管稳定剂、微管解聚/分解抑制剂、DNA嵌入剂、雄激素受体拮抗剂、化学保护剂、HDAC(组蛋白去乙酰化酶)抑制剂、DPP(二肽基二肽基肽酶)抑制剂、DPP-4抑制剂、BTK(布鲁顿酪氨酸激酶)抑制剂、激酶抑制剂如伊马替尼、酪氨酸激酶抑制剂如尼罗替尼、ARP(聚(ADP-核糖)聚合酶)抑制剂、CDK(细胞周期蛋白依赖性激酶)抑制剂、CDK4抑制剂、CDK6抑制剂、CDK4/6抑制剂、HIF1α(缺氧诱导因子1-α)抑制剂、DNA连接酶抑制剂、DNA连接酶IV抑制剂、NHEJ(非同源末端连接)抑制剂、DNA连接酶IV、NHEJ抑制剂和RAF抑制剂、TKI和RAF抑制剂、TKI和RAF抑制剂如索拉非尼、PDT(光动力疗法)敏化剂、ATR(共济失调毛细血管扩张症和Rad3相关蛋白激酶)抑制剂或任何前述的组合。
化合物(1)或其药物组合物可与一种或多种化疗剂联合施用,诸如例如VEGFR抑制剂,诸如呋喹替尼、莫特塞尼/AMG-706、瓦他拉尼;RTK抑制剂,诸如帕那替尼;钠通道阻滞剂,诸如GS967;FAK抑制剂,诸如TAE226;GLI1和GLI2抑制剂,诸如GANT61;MEK抑制剂,诸如比米替尼;RTA抑制剂,诸如利尼伐尼;ALK抑制剂,诸如布格替尼;溴丙酮酸;DNA烷化剂,诸如噻替派;核转移因素,诸如JSH-23;PORCn抑制剂,诸如Wnt-C59;5α-还原酶抑制剂,诸如度他雄胺;拓扑异构酶抑制剂,诸如卡柔比星;RAS抑制剂,诸如Kobe0065;CerK抑制剂,诸如NVP-231;AKT抑制剂,诸如优普色替;EZH2抑制剂,诸如GSK-503;BET溴结构域抑制剂,诸如OTX015;MEK5/ERK5抑制剂,诸如BIX02189;Syl/JAK抑制剂,诸如赛度替尼;IDO1抑制剂,诸如NLG919;视黄醛X受体活化剂,诸如贝沙罗汀;PGP抑制剂,诸如盐酸阿替米胺或盐酸阿考替胺;Erk抑制剂,诸如SCH772984;PI3K抑制剂,诸如gedatolisib;JAK抑制剂,诸如鲁索利替尼;AKT抑制剂,诸如afuresertib或afuresertib盐酸盐;ALK1抑制剂,诸如色瑞替尼;HDAC抑制剂,诸如艾贝司他;DPP抑制剂,诸如奥格列汀;EGFR抑制剂,诸如吉非替尼;EZH2抑制剂,诸如GSK126;BTK抑制剂,诸如依鲁替尼;激酶抑制剂,诸如盐酸伊马替尼;IDO抑制剂,诸如INCB024360;DNA交联剂,诸如丝裂霉素C;酪氨酸激酶抑制剂,诸如尼罗替尼;PARP抑制剂,诸如奥拉帕尼;微管蛋白稳定促进剂,诸如紫杉醇;CDK4/6抑制剂,诸如帕博西尼;RTK抑制剂,诸如舒尼替尼;PDT敏化剂,诸如他拉泊芬;p-糖蛋白抑制剂,诸如tariquidar;ATR抑制剂,诸如VE-822;HDAC抑制剂,诸如PCI-24781;DPP抑制剂,诸如奥格列汀;EGFR抑制剂,诸如gefinib;EZH2抑制剂,诸如GSK126;BTK抑制剂,诸如依鲁替尼;IDO抑制剂,诸如INCB024360;或任何前述的组合。
化合物(1)或其药物组合物可以与另一种化疗剂联合施用,诸如例如N-乙酰半胱氨酸(NAC)、阿霉素、阿仑单抗、氨磷汀、三氧化二砷、抗坏血酸、苯达莫司汀、贝伐单抗、硼替佐米、白消安、丁硫氨酸-亚砜亚胺、卡非佐米、卡莫司汀、氯法拉滨、环磷酰胺、环孢菌素、阿糖胞苷、达沙替尼、放线菌素、去纤苷酸、地塞米松、多西他赛、多柔比星、依托泊苷、非格司亭、氟尿苷、氟达拉滨、吉西他滨、干扰素α、易普利姆玛、来那度胺、亚叶酸、美法仑、霉酚酸酯、紫杉醇、帕利夫明、帕比司他、培非格司亭、泼尼松龙、泼尼松、来那度胺、利妥昔单抗、西罗莫司、2-巯基乙烷磺酸钠(MESNA)、硫代硫酸钠、他克莫司、替莫唑胺、沙利度胺、硫鸟嘌呤、噻替派、拓扑替康、万珂或任何前述的组合。
化合物(1)或其药物组合物可与其他化疗剂一起在组合治疗中使用,该化疗剂包括一种或多种抗代谢物,诸如叶酸类似物;嘧啶类似物,诸如氟尿嘧啶、氟尿苷和胞嘧啶阿糖胞苷;嘌呤类似物,诸如巯基嘌呤、硫鸟嘌呤和喷司他丁;天然产物,诸如长春花碱、长春新碱、依托泊苷、tertiposide、放线菌素D、道诺霉素、多柔比星、博莱霉素、mithamycin、丝裂霉素C、L-天冬酰胺酶和干扰素α;铂配位络合物,诸如顺铂和卡铂;米托蒽醌;羟基脲;甲基苄肼;激素和拮抗剂,诸如泼尼松、己酸羟孕酮、醋酸甲羟孕酮、醋酸甲地孕酮、己烯雌酚、乙炔雌二醇、他莫昔芬、丙酸睾酮、氟甲睾酮、氟他胺和亮丙瑞林;抗血管生成剂或抑制剂,诸如血管抑素、视黄酸、紫杉醇、雌二醇衍生物和噻唑并嘧啶衍生物;凋亡预防剂;雷公藤内酯;秋水仙碱;卢利康唑;和放射疗法。
化合物(1)或其药物组合物可以与抑制DNA修复的化合物诸如例如O6-苄基鸟嘌呤(O6-BG)共同施用。
化合物(1)或其药物组合物可以与一种或多种化疗剂联合施用,诸如例如阿巴瑞克、阿比特龙、醋酸阿比特龙、正乙酰半胱氨酸、盐酸阿柔比星、阿霉素、腺嘌呤、阿法替尼、马来酸阿法替尼、阿仑单抗、阿仑膦酸钠、阿利维A酸、别嘌醇钠、六甲蜜胺、氨磷汀、氨鲁米特、氨基乙酰丙酸、氨柔比星、安吖啶、阿那曲唑、血管抑素、阿普斯特、阿瑞匹坦、三氧化二砷、抗坏血酸、l-天冬酰胺酶、阿扎胞苷、硫唑嘌呤钠、巴多昔芬(serm)、贝利司他、盐酸苯达莫司汀、O6-苄基鸟嘌呤、贝伐单抗、贝沙罗汀、比卡鲁胺、比立考达、硫酸博莱霉素、硼替佐米、博舒替尼、溴夫定、布舍瑞林、白消安、丁硫氨酸-亚砜亚胺、卡巴他赛、卡博替尼、卡培他滨、卡铂、卡波醌、卡非佐米、卡莫氟、卡莫司汀、色瑞替尼、苯丁酸氮芥、顺铂、克拉屈滨、氯屈膦酸二钠、氯法拉滨、克唑替尼、环磷酰胺、环孢菌素、阿糖胞苷、胞嘧啶阿拉伯糖苷、达拉非尼、达卡巴嗪、放线菌素D、达沙替尼、放线菌素D、道诺霉素、地西他滨、去纤苷酸、醋酸地加瑞克、地塞米松、盐酸右雷佐生、地吖醌、己烯雌酚、多西他赛、去氧氟尿苷、盐酸多柔比星、多柔比星游离碱、屈他雄酮丙酸酯、度他雄胺、艾曲波帕、恩杂鲁胺、盐酸表柔比星、甲磺酸艾日布林、盐酸埃罗替尼、雌莫司汀磷酸钠、乙炔雌二醇、磷酸依托泊苷、依托泊苷、伊维莫司、依西美坦、芬太尼、非格司亭、芬戈莫德、氟尿苷、磷酸氟达拉滨、氟尿嘧啶、氟甲睾酮、氟他胺、福美司坦、甲酰美法仑、福沙吡坦、福莫司汀、氟维司群、吉非替尼、盐酸吉西他滨、吉西他滨游离碱、谷胱甘肽、磷酰胺氮芥、甘磷酰芥、醋酸戈舍瑞林、盐酸格拉司琼、庚铂、5-氨基乙酰丙酸己酯、醋酸组氨瑞林、己酸羟孕酮、羟基脲、伊班膦酸钠、依鲁替尼、埃克替尼、盐酸依达比星、艾代拉里斯、碘苷、异环磷酰胺、干扰素α、甲磺酸伊马替尼、咪喹莫特、巨大戟醇甲基丁烯酸酯、易普利姆玛、盐酸伊立替康、伊沙匹隆、醋酸兰瑞肽、拉帕替尼游离碱、二甲苯磺酸拉帕替尼、拉索昔芬、来那度胺、来曲唑、亚叶酸钙、醋酸亮丙瑞林、盐酸左旋咪唑、左旋亚叶酸钙、碘苄胍、洛铂、洛莫司汀、马罗匹坦、马索罗酚、盐酸氮芥、醋酸甲地孕酮、醋酸甲羟孕酮、盐酸美法仑、巯嘌呤、巯乙磺酸钠、甲氨蝶呤、甲氧沙林、氨基乙酰丙酸甲酯、亚甲蓝、异甲靛、米伐木肽、米替福新、米铂、光神霉素、二溴甘露醇、丝裂霉素C、米托坦、盐酸米托蒽醌、霉酚酸酯、nabiximols、那法瑞林、诺龙、奈达铂、奈拉滨、奈妥吡坦、尼罗替尼、尼鲁米特、尼莫司汀、尼达尼布、诺考达唑、奥曲肽、奥拉帕尼、高三尖杉酯碱、盐酸昂丹司琼、奥沙利铂、紫杉醇、帕博西尼、帕利夫明、盐酸帕洛诺司琼、帕米膦酸二钠、帕比司他、帕瑞肽、盐酸帕唑帕尼、聚乙二醇化非格司亭、培美曲塞二钠、喷司他丁、培洛霉素、哌泊溴烷、吡柔比星、普乐沙福、普卡霉素、泊马度胺、帕纳替尼、卟吩姆钠、泊非霉素、普拉曲沙、泼尼莫司汀、泼尼松龙、泼尼松、盐酸甲基苄肼、盐酸喹高利特、雷洛昔芬、雷替曲塞、拉多替尼、雷莫司汀、维甲酸、来那度胺、利妥昔单抗、罗米地辛、鲁索利替尼、磷酸鲁索利替尼、司莫司汀、西罗莫司、硫代硫酸钠、索拉非尼游离碱、索拉非尼甲苯磺酸酯、链脲菌素、舒芬太尼、舒尼替尼、他克莫司、他拉泊芬钠、他米巴罗汀、柠檬酸他莫昔芬、他喷他多、替莫泊芬、替莫唑胺、替西罗莫司、替尼泊苷、特立氟胺、替尼泊苷、睾内酯、丙酸睾酮、沙利度胺、硫鸟嘌呤、噻替派、胸腺法新、磷酸托西尼布、盐酸拓扑替康、柠檬酸托瑞米芬、曲贝替定、曲美替尼、维甲酸、曲洛司坦、曲普瑞林、托烷司琼、乌拉莫司汀、戊柔比星、凡德他尼、维多汀、维莫非尼、维替泊芬、长春花碱、硫酸长春新碱、长春新碱游离碱、长春地辛、酒石酸长春瑞滨、伏立诺他和唑来膦酸。
式(1)的化合物或其药物组合物可以与一种或多种化疗剂联合施用,该化疗剂诸如例如玻玛西尼、醋酸阿比特龙、ABVD、ABVE、ABVE-PC、AC、阿卡拉布替尼、AC-T、ADE、曲妥珠单抗-美坦新偶联物、马来酸阿法替尼、阿地白介素、艾乐替尼、阿仑单抗、alpelisib、氨磷汀、氨基乙酰丙酸盐酸盐、阿那曲唑、阿帕鲁胺、阿瑞匹坦、三氧化二砷、软腐欧文氏菌天冬酰胺酶、阿特珠单抗、阿维鲁单抗、axicabtagene ciloleucel、阿西替尼、阿扎胞苷、BEACOPP、贝利司他、盐酸苯达莫司汀、BEP、贝伐单抗、、比卡鲁胺、比米替尼、硫酸博莱霉素、博纳吐单抗、硼替佐米、博舒替尼、本妥昔单抗、布加替尼、BuMel、白消安、卡巴他赛、苹果酸卡博替尼、CAF、calaspargase pegol-mknl、卡培他滨、caplacizumab-yhdp、CAPOX、卡铂、卡铂-紫杉醇、卡非佐米、卡莫司汀、卡莫司汀植入物、CEM、cemiplimab-rwlc、色瑞替尼、西妥昔单抗、CEV、苯丁酸氮芥、苯丁酸氮芥-泼尼松、CHOP、顺铂、克拉屈滨、氯法拉滨、CMF、考比替尼、盐酸库潘尼西、COPDAC、COPP、COPP-ABV、克唑替尼、CVP、环磷酰胺、阿糖胞苷、阿糖胞苷脂质体、甲磺酸达拉非尼、达卡巴嗪、达克替尼、放线菌素D、达雷木单抗、阿法达贝泊汀、达沙替尼、盐酸道诺霉素、盐酸道诺霉素和阿糖胞苷脂质体、地西他滨、去纤苷酸钠、地加瑞克、地尼白介素、地诺单抗、地塞米松、盐酸右雷佐生、地努图希单抗、多西他赛、盐酸多柔比星、盐酸多柔比星脂质体、德瓦鲁单抗、度维利塞、埃罗妥珠单抗、艾曲波帕乙醇胺、emapalumab-lzsg、恩西地平、康奈非尼、恩杂鲁胺、盐酸表柔比星、EPOCH、阿法依伯汀、厄达替尼、甲磺酸艾日布林、盐酸埃罗替尼、依托泊苷、磷酸依托泊苷、伊维莫司、依西美坦、fec、非格司亭、磷酸氟达拉滨、氟尿嘧啶注射液、局部氟尿嘧啶、氟他胺、folfiri、folfiri-贝伐单抗、folfiri-、folfirinox、folfox、福他替尼二钠、FU-LV、氟维司群、吉非替尼、盐酸吉西他滨、吉西他滨-顺铂、吉西他滨-奥沙利铂、吉妥单抗、富马酸吉特替尼、马来酸格拉吉布、谷卡匹酶、醋酸戈舍瑞林、格拉司琼、HPV二价疫苗、HPV二价疫苗、重组HPV九价疫苗、HPV九价疫苗、重组HPV四价疫苗、重组HPV四价疫苗、羟基脲、hyper-CVAD、替伊莫单抗、依鲁替尼、ICE、盐酸伊达比星、艾代拉里斯、异环磷酰胺、甲磺酸伊马替尼、咪喹莫特、奥英妥珠单抗、干扰素α-2b重组体、碘苄胍131I、易普利姆玛、盐酸伊立替康、盐酸伊立替康脂质体、易武西单抗、伊沙匹隆、柠檬酸伊沙唑米、JEB、醋酸兰瑞肽、二甲苯磺酸拉帕替尼、硫酸拉罗替尼、来那度胺、甲磺酸乐伐替尼、来曲唑、亚叶酸钙、醋酸亮丙瑞林、洛莫司汀、劳拉替尼、镥177注射液、盐酸氮芥、醋酸甲地孕酮、美法仑、盐酸美法仑、巯嘌呤、mesna、甲氨蝶呤、溴化甲基纳曲酮、米哚妥林、丝裂霉素c、盐酸米托蒽醌、莫戈美珠单抗、moxetumomab pasudotox-tdfk、MVAC、耐昔妥珠单抗、奈拉滨、马来酸来那替尼、netupitant和盐酸帕洛诺司琼、尼罗替尼、尼鲁米特、甲苯磺酸尼拉帕尼一水合物、纳武单抗、奥滨尤妥珠单抗、OEPA、奥法木单抗、OFF、奥拉帕尼、奥拉单抗、高三尖杉酯碱、盐酸昂丹司琼、OPPA、甲磺酸奥希替尼、奥沙利铂、紫杉醇、紫杉醇白蛋白稳定的纳米颗粒制剂、PAD、帕博西尼、帕利夫明、盐酸帕洛诺司琼、盐酸帕洛诺司琼和netupitant、帕米膦酸二钠、帕尼单抗、帕比司他、盐酸帕唑帕尼、PCV、PEB、培门冬酶、聚乙二醇化非格司亭、聚乙二醇干扰素α-2b、帕博利珠单抗、培美曲塞二钠、帕妥珠单抗、普乐沙福、polatuzumab vedotin-piiq、泊马度胺、盐酸帕纳替尼、普拉曲沙、泼尼松、盐酸甲基苄肼、盐酸普萘洛尔、二氯化镭223、盐酸雷洛昔芬、雷莫芦单抗、拉布立酶、依库丽单抗、R-CHOP、R-CVP、重组HPV二价疫苗、重组HPV九价疫苗、重组HPV四价疫苗、重组干扰素α-2b、瑞格非尼、R-EPOCH、瑞博西尼、R-ICE、利妥昔单抗、利妥昔单抗和人透明质酸酶、盐酸罗拉吡坦、罗米地辛、罗米司亭、樟脑磺酸瑞卡帕布、磷酸鲁索利替尼、司妥昔单抗、sipuleucel-t、索尼得吉、甲苯磺酸索拉非尼、STANFORD V、苹果酸舒尼替尼、TAC、tagraxofusp-erzs、甲苯磺酸他拉唑帕尼、滑石、拉他莫金、柠檬酸他莫昔芬、替莫唑胺、替西罗莫司、沙利度胺、硫鸟嘌呤、噻替派、tisagenlecleucel、托珠单抗、盐酸拓扑替康、托瑞米芬、TPF、曲贝替定、曲美替尼、曲妥珠单抗、曲妥珠单抗和透明质酸酶-oysk、三氟尿苷和盐酸替比嘧啶、尿苷三乙酸酯、VAC、戊柔比星、VAMP、凡德他尼、VeIP、维莫非尼、维奈托克、硫酸长春花碱、硫酸长春新碱脂质体、酒石酸长春瑞滨、vip、维莫德吉、伏立诺他、XELIRI、XELOX、阿柏西普、唑来膦酸以及任何前述的组合。
施用化合物(1)或其药物组合物用于治疗癌症、炎性疾病或自身免疫性疾病的功效可通过使用体外和动物研究并在临床试验中进行评估。
本公开提供的抑制p38αMAPK的方法包括使p38αMAPK与本公开提供的化合物接触以到达p38αMAPK的ED底物对接位点附近的口袋。
本公开提供的抑制p38αMAPK的方法不会导致p38α依赖性反调节应答的丧失。p38α依赖性反调节应答与丝裂原和应激活化的蛋白激酶-I(MSK1)或MSK2相关。在靶向p38α的ED底物对接位点附近的口袋时,本公开提供的抑制剂避免干扰CD特异性底物(包括MSK1/2),从而通过IL-10和DUSP2的表达限制炎症。
本发明的方面
本发明由以下方面进一步限定。
方面1.一种化合物,其为结晶5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐二水合物:
方面2.根据方面1所述的化合物,其中该化合物由XRPD图案表征,该XRPD图案包含至少在10.5°±0.2°、13.9°±0.2°、14.8°±0.2°、17.2±0.2°、20.4±0.2°、22.6±0.2°、25.7±0.2°和27.9±0.2°处的以2θ角表示并且使用Cu-Kα辐射确定的特征衍射峰。
方面3.根据方面1所述的化合物,其中该化合物由XRPD图案表征,该XRPD图案包含至少在10.5°±0.1°、13.9°±0.1°、14.8°±0.1°、17.2±0.1°、20.4±0.1°、22.6±0.1°、25.7±0.1°和27.9±0.2°处的以2θ角表示并且使用Cu-Kα辐射确定的特征衍射峰。
方面4.根据方面1所述的化合物,其中该化合物由XRPD图案表征,该XRPD图案包含至少在7.5±0.2°、8.5±0.2°、10.5°±0.2°、12.8±0.2°、13.9°±0.2°、14.8°±0.2°、15.5±0.2°、17.2±0.2°、18.2±0.2°、20.1±0.2°、20.4±0.2°、21.1±0.2°、22.6±0.2°、22.9±0.2°、23.5±0.2°、23.8±0.2°、24.6±0.2°、25.7±0.2°、26.1±0.2°、26.4±0.2°、27.1±0.2°、27.5±0.2°、27.9±0.2°和32.4±0.2°处的以2θ角表示并且使用Cu-Kα辐射确定的特征衍射峰。
方面5.根据方面1所述的化合物,其中该化合物由XRPD图案表征,该XRPD图案包含至少在7.5±0.1°、8.5±0.1°、10.5°±0.1°、12.8±0.1°、13.9°±0.1°、14.8°±0.1°、15.5±0.1°、17.2±0.1°、18.2±0.1°、20.1±0.1°、20.4±0.1°、21.1±0.1°、22.6±0.1°、22.9±0.1°、23.5±0.1°、23.8±0.1°、24.6±0.1°、25.7±0.1°、26.1±0.1°、26.4±0.1°、27.1±0.1°、27.5±0.1°、27.9±0.1°和32.4±0.1°处的以2θ角表示并且使用Cu-Kα辐射确定的特征衍射峰。
方面6.根据方面1至5中任一项所述的化合物,其中该化合物由基本上如图1所示的XRPD图案表征。
方面7.根据方面1至6中任一项所述的化合物,其中该化合物具有例如161℃至167℃的熔融起始温度,其中该熔融起始温度通过差示扫描量热法确定。
方面8.根据方面1至6中任一项所述的化合物,其中该化合物具有例如164.3℃±0.5℃的熔融起始温度,其中该熔融起始温度通过差示扫描量热法确定。
方面9.根据方面1至8中任一项所述的化合物,其中该化合物具有例如89J/g至99J/g的熔融焓,其中该熔融焓通过差示扫描量热法确定。
方面10.根据方面1至8中任一项所述的化合物,其中该化合物具有例如94.25J/g±0.5J/g的熔融焓,其中该熔融焓通过差示扫描量热法确定。
方面11.根据方面1至10中任一项所述的化合物,其中该化合物具有例如178.5J/g至184.5J/g的熔融峰,其中该熔融峰通过差示扫描量热法确定。
方面12.根据方面1至10中任一项所述的化合物,其中该化合物具有例如在181.6℃±2.0℃的熔融峰,其中该熔融峰通过差示扫描量热法确定。
方面13.根据方面1至12中任一项所述的化合物,其中该化合物表现出基本上如图2所示的差示扫描量热曲线。
方面14.根据方面1至13中任一项所述的化合物,其中该化合物在25℃至210℃的温度下具有例如13%至15%的重量损失,其中该重量损失通过热重分析以2℃/min的扫描速率确定。
方面15.根据方面1至13中任一项所述的化合物,其中该化合物在25℃至210℃的温度下具有例如13.9%±1.0%的重量损失,其中该重量损失通过热重分析以2℃/min的扫描速率确定。
方面16.根据方面1至15中任一项所述的化合物,其中该化合物表现出基本上如图3所示的差热量热曲线。
方面17.根据方面1至16中任一项所述的化合物,其中该化合物在25℃至122℃的温度下具有例如2%至6%的重量损失,其中该重量损失通过热重分析以4.25℃/min的扫描速率确定。
方面18.根据方面1至16中任一项所述的化合物,其中该化合物在25℃至122℃的温度下具有例如4.25%±1.0%的重量损失,其中该重量损失通过热重分析以4.25℃/min的扫描速率确定。
方面19.根据方面1至16中任一项所述的化合物,其中该化合物表现出基本上如图4所示的差热量热曲线。
方面20.一种药物组合物,其包含根据方面1至19中任一项所述的化合物。
方面21.根据方面1至19中任一项所述的药物组合物,其中该药物组合物包含治疗有效量的该化合物以用于治疗患者的疾病。
方面22.根据方面21所述的药物组合物,其中该疾病通过抑制p38αMAPK受体来治疗。
方面23.根据方面21所述的药物组合物,其中该疾病是癌症。
方面24.根据方面21所述的药物组合物,其中该疾病是炎性疾病。
方面25.根据方面21所述的药物组合物,其中该疾病是自身免疫性疾病。
方面26.根据方面21所述的药物组合物,其中该疾病选自急性肺损伤、急性呼吸窘迫综合征(ARDS)和慢性阻塞性肺病(COPD)。
方面27.一种治疗患者的疾病的方法,其包括向需要此类治疗的患者施用治疗有效量的根据方面1至19中任一项所述的化合物,其中该疾病通过抑制p38αMAPK受体来治疗。
方面28.一种治疗患者的疾病的方法,其包括向需要此类治疗的患者施用治疗有效量的根据方面1至19中任一项所述的化合物,其中该疾病是癌症。
方面29.根据方面28所述的方法,其中该癌症选自乳腺癌和黑色素瘤。
方面30.一种治疗患者的疾病的方法,其包括向需要此类治疗的患者施用治疗有效量的根据方面1至19中任一项所述的化合物,其中该疾病是炎性疾病。
方面31.根据方面30所述的方法,其中该炎性疾病选自急性呼吸窘迫综合征、局灶性节段性肾小球肾炎、动脉粥样硬化/急性冠脉综合征、慢性阻塞性肺病、哮喘、炎性肠病、克罗恩病、银屑病、狼疮、多发性硬化症、高胆固醇血症的炎症、疼痛、糖尿病和类风湿性关节炎。
方面32.一种治疗患者的疾病的方法,其包括向需要此类治疗的患者施用治疗有效量的根据方面1至19中任一项所述的化合物,其中该疾病是自身免疫性疾病。
方面33.一种治疗患者的疾病的方法,其包括向需要此类治疗的患者施用治疗有效量的根据方面1至19中任一项所述的化合物,其中该疾病是年龄相关性疾病。
方面34.根据方面33所述的方法,其中该年龄相关性疾病选自听力损失、肌肉退化、沃纳综合征、细胞老化和阿尔茨海默病。
方面35.一种治疗患者的疾病的方法,其包括向需要此类治疗的患者施用治疗有效量的根据方面1至19中任一项所述的化合物,其中该疾病选自急性肺损伤、急性呼吸窘迫综合征(ARDS)和慢性阻塞性肺病(COPD)。
方面36.一种抑制p38αMAPK受体的方法,其包括使p38αMAPK受体与根据方面1至19中任一项所述的化合物接触。
方面37.一种抑制患者的p38αMAPK受体的方法,其包括向该患者施用药理学有效量的根据方面1至19中任一项所述的化合物。
方面38.根据方面37所述的方法,其中抑制该p38αMAPK受体包括选择性抑制该p38αMAPK受体。
方面39.根据方面38所述的方法,其中抑制该p38αMAPK受体不会导致p38α依赖性反调节应答的丧失。
方面40.根据方面39所述的方法,其中该p38α依赖性反调节应答涉及丝裂原和应激活化的蛋白激酶-1(MSK1)或MSK2。
方面41.根据方面37至40中任一项所述的方法,其中抑制该p38αMAPK受体稳定内皮或上皮屏障功能。
方面42.根据方面37至41中任一项所述的方法,其中抑制该p38αMAPK受体减少炎症。
方面43.根据方面37至42中任一项所述的方法,其中抑制该p38αMAPK受体减轻KPS诱导的肺损伤。
方面44.根据方面37至43中任一项所述的方法,其中抑制该p38αMAPK受体调节白细胞运输。
方面45.根据方面37至44中任一项所述的方法,其中抑制该p38αMAPK受体调节细胞因子表达。
实例
下面的实例详细描述了制备结晶5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐二水合物盐的方法、本公开提供的结晶盐的性质以及使用本公开提供的结晶盐的方法。对于本领域技术人员来说显而易见的是,在不脱离本发明的范围的情况下,可以对材料和方法两者进行许多修改。
实例1
化合物(1)的制备
化合物(1)根据PCT国际公开号PCT/US2019/064960的第[00277]段中公开的方案5制备。
在25℃至30℃的惰性气氛下,将4-硝基苄基氯(1.0eq)添加到异丙醇(5.0vol)中。将溶液搅拌15min并缓慢添加2.1eq吗啉,同时将温度保持在25℃至30℃。将混合物加热至65℃并通过TLC/HPLC监测反应进程。提供4-(4-硝基苄基)吗啉的反应在3小时后完成。
将甲醇中的4-(4-硝基苄基)吗啉在65℃暴露于雷尼镍以提供4-(吗啉代甲基)苯胺。
使4-(吗啉代甲基)苯胺和5-(二甲基氨基)萘-1-磺酰氯与丹磺酰氯在叔胺碱(诸如N-甲基吗啉)存在下于二氯甲烷中反应,以提供5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺。
使5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺与于1,4-二噁烷中的4M HCl在甲醇中在0℃至25℃的温度下反应以提供5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐。
将二盐酸盐(1eq)悬浮在甲醇(3vol)和水(2eq)中,并将悬浮液在20℃至30℃搅拌1小时以提供结晶5-(二甲基氨基)-N-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐二水合物。将固体过滤并用甲醇(1.5vol)洗涤。
X射线粉末衍射(XRPD)使用具有闪烁探测器的Shimadzu Lab XRD-6100仪器在连续扫描模式下使用Cu/K-α源进行。以2deg/min的扫描速度、0.02deg的采样间距和0.6sec的预设时间在3°至50°的扫描范围内获得衍射图案。该方法用于获得图1、5和7中呈现的XRPD图案,并且数据用于推导图9至10中呈现的晶体结构。
使用Perkin Elmer DSC 4000(版本13.2.1.0007)仪器在30℃至300℃的温度范围内以5℃/min的加热速率和80mL/min的氮气流速使用3mg至4mg的样品质量进行差示扫描量热法(DSC)。该方法用于获得图4和6中呈现的DSC曲线。
使用Shimadzu DTG-60仪器在低于25℃至400℃的温度范围内以2℃/min的加热速率使用10mg的样品质量进行差示热重分析(TGA)。该方法用于提供图2和3中呈现的TGA曲线。
最后,应当注意,存在实现本文公开的实施例的替代方式。因此,本实施例被认为是说明性而非限制性的,并且权利要求书不限于本文中给出的详细信息,而是可以在该权利要求书的范围和等效物内进行修改。
Claims (45)
2.根据权利要求1所述的化合物,其中所述化合物由XRPD图案表征,所述XRPD图案包含至少在10.5°±0.2°、13.9°±0.2°、14.8°±0.2°、17.2±0.2°、20.4±0.2°、22.6±0.2°、25.7±0.2°和27.9±0.2°处的以2θ角表示并且使用Cu-Kα辐射确定的特征衍射峰。
3.根据权利要求1所述的化合物,其中所述化合物由XRPD图案表征,所述XRPD图案包含至少在10.5°±0.1°、13.9°±0.1°、14.8°±0.1°、17.2±0.1°、20.4±0.1°、22.6±0.1°、25.7±0.1°和27.9±0.2°处的以2θ角表示并且使用Cu-Kα辐射确定的特征衍射峰。
4.根据权利要求1所述的化合物,其中所述化合物由XRPD图案表征,所述XRPD图案包含至少在7.5±0.2°、8.5±0.2°、10.5°±0.2°、12.8±0.2°、13.9°±0.2°、14.8°±0.2°、15.5±0.2°、17.2±0.2°、18.2±0.2°、20.1±0.2°、20.4±0.2°、21.1±0.2°、22.6±0.2°、22.9±0.2°、23.5±0.2°、23.8±0.2°、24.6±0.2°、25.7±0.2°、26.1±0.2°、26.4±0.2°、27.1±0.2°、27.5±0.2°、27.9±0.2°和32.4±0.2°处的以2θ角表示并且使用Cu-Kα辐射确定的特征衍射峰。
5.根据权利要求1所述的化合物,其中所述化合物由XRPD图案表征,所述XRPD图案包含至少在7.5±0.1°、8.5±0.1°、10.5°±0.1°、12.8±0.1°、13.9°±0.1°、14.8°±0.1°、15.5±0.1°、17.2±0.1°、18.2±0.1°、20.1±0.1°、20.4±0.1°、21.1±0.1°、22.6±0.1°、22.9±0.1°、23.5±0.1°、23.8±0.1°、24.6±0.1°、25.7±0.1°、26.1±0.1°、26.4±0.1°、27.1±0.1°、27.5±0.1°、27.9±0.1°和32.4±0.1°处的以2θ角表示并且使用Cu-Kα辐射确定的特征衍射峰。
6.根据权利要求1至5中任一项所述的化合物,其中所述化合物由基本上如图1所示的XRPD图案表征。
7.根据权利要求1至6中任一项所述的化合物,其中所述化合物具有161℃至167℃的熔融起始温度,其中所述熔融起始温度通过差示扫描量热法确定。
8.根据权利要求1至6中任一项所述的化合物,其中所述化合物具有164.3℃±0.5℃的熔融起始温度,其中所述熔融起始温度通过差示扫描量热法确定。
9.根据权利要求1至8中任一项所述的化合物,其中所述化合物具有89J/g至99J/g的熔融焓,其中所述熔融焓通过差示扫描量热法确定。
10.根据权利要求1至8中任一项所述的化合物,其中所述化合物具有94.25J/g±0.5J/g的熔融焓,其中所述熔融焓通过差示扫描量热法确定。
11.根据权利要求1至10中任一项所述的化合物,其中所述化合物具有178.5J/g至184.5J/g的熔融峰,其中所述熔融峰通过差示扫描量热法确定。
12.根据权利要求1至10中任一项所述的化合物,其中所述化合物具有在181.6℃±2.0℃的熔融峰,其中所述熔融峰通过差示扫描量热法确定。
13.根据权利要求1至12中任一项所述的化合物,其中所述化合物表现出基本上如图2所示的差示扫描量热曲线。
14.根据权利要求1至13中任一项所述的化合物,其中所述化合物在25℃至210℃的温度下具有13%至15%的重量损失,其中所述重量损失通过热重分析以2℃/min的扫描速率确定。
15.根据权利要求1至13中任一项所述的化合物,其中所述化合物在25℃至210℃的温度下具有13.9%±1.0%的重量损失,其中所述重量损失通过热重分析以2℃/min的扫描速率确定。
16.根据权利要求1至15中任一项所述的化合物,其中所述化合物表现出基本上如图3所示的差热量热曲线。
17.根据权利要求1至16中任一项所述的化合物,其中所述化合物在25℃至122℃的温度下具有2%至6%的重量损失,其中所述重量损失通过热重分析以4.25℃/min的扫描速率确定。
18.根据权利要求1至16中任一项所述的化合物,其中所述化合物在25℃至122℃的温度下具有4.25%±1.0%的重量损失,其中所述重量损失通过热重分析以4.25℃/min的扫描速率确定。
19.根据权利要求1至16中任一项所述的化合物,其中所述化合物表现出基本上如图4所示的差热量热曲线。
20.一种药物组合物,其包含根据权利要求1至19中任一项所述的化合物。
21.根据权利要求1至19中任一项所述的药物组合物,其中所述药物组合物包含治疗有效量的所述化合物以用于治疗患者的疾病。
22.根据权利要求21所述的药物组合物,其中所述疾病通过抑制p38αMAPK受体来治疗。
23.根据权利要求21所述的药物组合物,其中所述疾病是癌症。
24.根据权利要求21所述的药物组合物,其中所述疾病是炎性疾病。
25.根据权利要求21所述的药物组合物,其中所述疾病是自身免疫性疾病。
26.根据权利要求21所述的药物组合物,其中所述疾病选自急性肺损伤、急性呼吸窘迫综合征(ARDS)和慢性阻塞性肺病(COPD)。
27.一种治疗患者的疾病的方法,其包括向需要此类治疗的患者施用治疗有效量的根据权利要求1至19中任一项所述的化合物,其中所述疾病通过抑制所述p38αMAPK受体来治疗。
28.一种治疗患者的疾病的方法,其包括向需要此类治疗的患者施用治疗有效量的根据权利要求1至19中任一项所述的化合物,其中所述疾病是癌症。
29.根据权利要求28所述的方法,其中所述癌症选自乳腺癌和黑色素瘤。
30.一种治疗患者的疾病的方法,其包括向需要此类治疗的患者施用治疗有效量的根据权利要求1至19中任一项所述的化合物,其中所述疾病是炎性疾病。
31.根据权利要求30所述的方法,其中所述炎性疾病选自急性呼吸窘迫综合征、局灶性节段性肾小球肾炎、动脉粥样硬化/急性冠脉综合征、慢性阻塞性肺病、哮喘、炎性肠病、克罗恩病、银屑病、狼疮、多发性硬化症、高胆固醇血症的炎症、疼痛、糖尿病和类风湿性关节炎。
32.一种治疗患者的疾病的方法,其包括向需要此类治疗的患者施用治疗有效量的根据权利要求1至19中任一项所述的化合物,其中所述疾病是自身免疫性疾病。
33.一种治疗患者的疾病的方法,其包括向需要此类治疗的患者施用治疗有效量的根据权利要求1至19中任一项所述的化合物,其中所述疾病是年龄相关性疾病。
34.根据权利要求33所述的方法,其中所述年龄相关性疾病选自听力损失、肌肉退化、沃纳综合征、细胞老化和阿尔茨海默病。
35.一种治疗患者的疾病的方法,其包括向需要此类治疗的患者施用治疗有效量的根据权利要求1至19中任一项所述的化合物,其中所述疾病选自急性肺损伤、急性呼吸窘迫综合征(ARDS)和慢性阻塞性肺病(COPD)。
36.一种抑制p38αMAPK受体的方法,其包括使所述p38αMAPK受体与根据权利要求1至19中任一项所述的化合物接触。
37.一种抑制患者的p38αMAPK受体的方法,其包括向患者施用药理学有效量的根据权利要求1至19中任一项所述的化合物。
38.根据权利要求37所述的方法,其中抑制所述p38αMAPK受体包括选择性抑制所述p38αMAPK受体。
39.根据权利要求38所述的方法,其中抑制所述p38αMAPK受体不会导致p38α依赖性反调节应答的丧失。
40.根据权利要求39所述的方法,其中所述p38α依赖性反调节应答涉及丝裂原和应激活化的蛋白激酶-1(MSK1)或MSK2。
41.根据权利要求37至40中任一项所述的方法,其中抑制所述p38αMAPK受体稳定内皮或上皮屏障功能。
42.根据权利要求37至41中任一项所述的方法,其中抑制所述p38αMAPK受体减少炎症。
43.根据权利要求37至42中任一项所述的方法,其中抑制所述p38αMAPK受体减轻KPS诱导的肺损伤。
44.根据权利要求37至43中任一项所述的方法,其中抑制所述p38αMAPK受体调节白细胞运输。
45.根据权利要求37至44中任一项所述的方法,其中抑制所述p38αMAPK受体调节细胞因子表达。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063106991P | 2020-10-29 | 2020-10-29 | |
US63/106,991 | 2020-10-29 | ||
PCT/US2021/055950 WO2022093610A1 (en) | 2020-10-29 | 2021-10-21 | Crystalline 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl) naphthalene-1-sulfonmide di-hydrochloride di-hydrate |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116367838A true CN116367838A (zh) | 2023-06-30 |
Family
ID=78622064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180069848.8A Pending CN116367838A (zh) | 2020-10-29 | 2021-10-21 | 结晶5-(二甲基氨基)-n-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐二水合物 |
Country Status (8)
Country | Link |
---|---|
US (2) | US11390581B2 (zh) |
EP (1) | EP4237415A1 (zh) |
JP (1) | JP2023546835A (zh) |
CN (1) | CN116367838A (zh) |
AU (1) | AU2021370893B2 (zh) |
CA (1) | CA3196286A1 (zh) |
IL (1) | IL302235A (zh) |
WO (1) | WO2022093610A1 (zh) |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR96352E (fr) | 1967-12-29 | 1972-06-16 | Science Union & Cie | Nouveaux dérives du spiro (4,5) decane et leur procédé de préparation. |
DE19801646A1 (de) | 1998-01-17 | 1999-07-22 | Bayer Ag | Substituierte alpha,beta-annellierte Butyrolactone |
TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
KR20050100686A (ko) | 2003-02-13 | 2005-10-19 | 사노피-아벤티스 도이칠란트 게엠베하 | 질소-치환된헥사하이드로피라지노[1,2-a]피리미딘-4,7-디온 유도체,이의 제조방법 및 의약으로서의 이의 용도 |
US7297817B2 (en) | 2004-04-13 | 2007-11-20 | Cephalon France | Thio-substituted arylmethanesulfinyl derivatives |
WO2005100338A1 (en) | 2004-04-13 | 2005-10-27 | Astex Therapeutics Limited | 5-morpholinylmethylthiophenyl pharmaceutial compounds as p38 map kinase modulators |
US20090299063A1 (en) | 2005-03-29 | 2009-12-03 | Paul Shapiro | Inhibitors for Extracellular Signal-Regulated Kinase Docking Domains and Uses Therefor |
TW200904421A (en) | 2007-05-03 | 2009-02-01 | Astellas Pharma Inc | New compounds |
ES2427892T3 (es) | 2008-02-29 | 2013-11-04 | Chroma Therapeutics Limited | Inhibidores de MAP quinasa p38 |
WO2010082912A1 (en) | 2009-01-15 | 2010-07-22 | Avalon Pharmaceuticals | Derivatives of multi-ring aromatic compounds and uses as anti-tumor agents |
WO2010094977A1 (en) | 2009-02-23 | 2010-08-26 | Arrow Therapeutics Limited | Novel biphenyl compounds useful for the treatment of hepatitis c |
CN105308004A (zh) | 2013-01-15 | 2016-02-03 | 卡尔·亚历克斯·穆勒 | 利用紫外线辐射的氧化物的快速固态反应 |
CN106573914B (zh) | 2014-02-14 | 2021-05-28 | 瑞斯比维特有限公司 | 作为激酶抑制剂的吡唑基-脲 |
GB201417168D0 (en) | 2014-09-29 | 2014-11-12 | Univ Hertfordshire Higher Education Corp | Compounds |
WO2016073633A1 (en) | 2014-11-05 | 2016-05-12 | University Of Kansas | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) |
CN109640970B (zh) | 2016-06-23 | 2023-05-23 | 马里兰大学巴尔的摩分校 | 选择性p38α特异性MAPK抑制剂 |
EP3890733A4 (en) | 2018-12-07 | 2022-05-04 | University of Maryland, Baltimore | INHIBITORS OF P38 MITOGEN-ACTIVATED PROTEIN KINASE AT NON-ATP/CATALYTIC SITE |
US20230140941A1 (en) | 2020-03-13 | 2023-05-11 | University Of Maryland, Baltimore | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors |
CN116406355A (zh) | 2020-05-18 | 2023-07-07 | Gen1E生命科学公司 | P38α促分裂原活化蛋白激酶抑制剂 |
-
2021
- 2021-10-21 AU AU2021370893A patent/AU2021370893B2/en active Active
- 2021-10-21 CN CN202180069848.8A patent/CN116367838A/zh active Pending
- 2021-10-21 WO PCT/US2021/055950 patent/WO2022093610A1/en active Application Filing
- 2021-10-21 IL IL302235A patent/IL302235A/en unknown
- 2021-10-21 US US17/506,822 patent/US11390581B2/en active Active
- 2021-10-21 EP EP21807412.8A patent/EP4237415A1/en active Pending
- 2021-10-21 CA CA3196286A patent/CA3196286A1/en active Pending
- 2021-10-21 JP JP2023521835A patent/JP2023546835A/ja active Pending
-
2022
- 2022-05-12 US US17/743,035 patent/US20220267259A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2021370893A1 (en) | 2023-05-25 |
CA3196286A1 (en) | 2022-05-05 |
US11390581B2 (en) | 2022-07-19 |
WO2022093610A8 (en) | 2023-04-27 |
WO2022093610A1 (en) | 2022-05-05 |
AU2021370893B2 (en) | 2024-03-07 |
EP4237415A1 (en) | 2023-09-06 |
US20220267259A1 (en) | 2022-08-25 |
US20220135520A1 (en) | 2022-05-05 |
JP2023546835A (ja) | 2023-11-08 |
IL302235A (en) | 2023-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11286260B2 (en) | P38α mitogen-activated protein kinase inhibitors | |
JP2023546362A (ja) | 癌を治療するための組み合わせ療法 | |
AU2021345531B2 (en) | Solid forms of a CDK4 inhibitor | |
US11976049B2 (en) | Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors | |
EP3125901B1 (en) | Derivatives of cephalosporin for treating cancer | |
CN116367838A (zh) | 结晶5-(二甲基氨基)-n-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐二水合物 | |
TW202027750A (zh) | 治療癌症之套組及其方法 | |
AU2024203532A1 (en) | Crystalline 5-(dimethylamino) -n- (4-(morpholinomethyl)phenyl) naphthalene-1-sulfonamide di-hydrochloride di-hydrate | |
JP7289978B1 (ja) | がん治療のための併用療法 | |
AU2024203859A1 (en) | P38alpha mitogen-activated protein kinase inhibitors | |
WO2024015793A2 (en) | Enantiomer of azopodophyllotoxin derivative su056 | |
JP2023502264A (ja) | 固体用量医薬組成物 | |
JP2024502130A (ja) | チロシンキナーゼ非受容体1(tnk1)阻害剤の形態及び製剤 | |
WO2021155185A1 (en) | Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40096869 Country of ref document: HK |